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I. Risk Statement 
The Risk of Decompression Sickness (DCS) is identified by the NASA Human Research 
Program (HRP) as a recognized risk to human health and performance in space, as defined in the 
HRP Program Requirements Document (PRD). This Evidence Report provides a 
summary of the evidence that has been used to identify and characterize this risk. Given that 
tissue inert gas partial pressure is often greater than ambient pressure during phases of a mission, 
primarily during extravehicular activity (EVA), there is a possibility that decompression sickness 
may occur. 
II. Executive Summary 
When a diver returns from a hyperbaric environment or an aviator or astronaut travels to a 
hypobaric environment, the amount of inert gas in excess of what can be held in solution at the 
new lower pressure has the potential to come out of solution to form gas spaces that can displace 
or otherwise damage tissues. Unlike other spaceflight-related human risks, decompression 
sickness (DCS) is a known problem that has been mitigated since the first EVA. Various DCS 
mitigation strategies have effectively been used, including a lower pressure high oxygen 
environment (Gemini, Apollo, Skylab) requiring a single 4-hr pre-launch oxygen prebreathe 
(PB); a resting 4-hr in-suit PB; an intermediate pressure, mildly hypoxic environment requiring a 
single 40- to 75-min in-suit PB; and several exercise-enhanced protocols combining both mask 
and in-suit PB protocols. To date, DCS has been effectively mitigated through rigorous 
adherence to PB protocols validated specifically for the EVA environment and primarily for the 
microgravity (µG) environment. While effective, these protocols can be complex and require 
significant pre-flight training, inflight crew time, and consumable usage. 
 
Historically, prebreathe protocols have been developed with the goal of preventing DCS and 
have been designed to meet operational needs. This operationally driven research has left gaps in 
knowledge about several DCS risk factors, including bubble formation in space, nitrogen 
elimination in space, breaks in PB periods, micronuclei generation, and tissue saturation, across 
different pressure and gas environments. 
 
The acceptable risk for DCS has been defined in the NASA Human Spaceflight Standards; 
therefore, the next step will be to develop and validate procedures, protocols, and 
countermeasures to meet this standard effectively and efficiently for the range of nominal and 
off-nominal atmospheres and decompression profiles that crewmembers may experience during 
future exploration missions. Utilization of the Exploration Atmosphere (8.2 psia / 34% O2), suit 
ports, and variable pressure suits, as well as the inability to rapidly deorbit for medical treatment, 
means that existing DCS risk mitigation protocols and data sets are not applicable to future 
exploration missions.  
  
To improve efficiency from a sea level atmosphere, data are needed on the potential differences 
in bubble formation and N2 elimination while in µG. To improve safety and efficiency from any 
atmosphere, data are needed to describe the consequences of a break in PB. Finally, the 
opportunity exists to mitigate DCS primarily through engineering controls by the use of the 8.2 
psia / 34% O2 Exploration Atmosphere, suit ports, and variable-pressure EVA suit. While 
promising, this strategy still requires validation to ensure it mitigates the DCS risk to acceptable 
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levels and to determine if there are any significant negative physiological effects associated with 
the Exploration Atmosphere’s mild hypoxia equivalent to an altitude of approximately 4000 ft.  
 
III. Introduction 
 
The overarching medical and operational philosophy is that it is better to prevent rather than to 
treat DCS.  The advent of technology that permitted a rapid change in ambient pressure ushered 
in the study of new medical conditions, such as DCS and hypoxia.  Robert Hooke, an assistant 
researcher to Robert Boyle, created the first functional vacuum pump in 1671 (Harsch 2006).  
Much experimental work was done on exposure to a “rarified atmosphere.”  As the air 
compressor advanced, with steam engine power and later with electricity, it replaced the 
application of a bellows at the blacksmith’s hearth and soon found new uses including providing 
forced air to divers beneath the sea, allowing diving beyond ones’ breath-holding abilities as well 
as permitting experiments under hyperbaric conditions.  Paul Bert’s seminal treaties on 
barometric pressure in 1878 codified much of the empirical experience of that day (Bert 1878).  
Diving technology rapidly advanced that permitted deeper and longer exposures to hyperbaric air 
with the accompanying DCS on the return to 1 atmosphere absolute (ATA).  Several textbooks 
on diving chronicle the history of diving and the methods used to prevent DCS upon return to 1 
ATA, as well as treatment strategies to aid those afflicted with “the bends.”  A compilation of 
experience with hypobaric, or altitude, DCS was published by Fulton in 1951, succinctly titled, 
Decompression Sickness.  No other book has since been published that surpasses the depth and 
breadth of information that lies between the covers of Fulton’s book.  Much of what we know 
about hypobaric DCS and denitrogenation as a mitigation strategy was learned during and 
shortly after World War II (WWII) and was summarized in Fulton’s book.  Numerous chapters 
and reports have since been published that include new observations (evidence) for hypobaric 
DCS, summarized in the following pages.  
 
Before the very first EVA, NASA understood that DCS was a risk to be mitigated. Given the 
highly constrained spaceflight environment, these mitigation strategies needed to be efficient 
both in time and resource use. A clear understanding of the mechanisms that cause DCS is 
needed to efficiently mitigate this potentially catastrophic risk to the mission and the astronaut. 
Should DCS occur in the spaceflight environment, it would occur during an EVA, when the 
crewmember is already isolated from the habitat in a physically constraining spacesuit. 
Historically, treatment for DCS could only begin once the EVA crewmember had terminated 
EVA activities and returned to the habitat to be repressurized. 
  
A. DCS Signs and Symptoms 
DCS signs and symptoms are historically classified as Type I, Type II, and skin bends.  At JSC, 
Type I symptoms are described as “pain only” DCS symptoms localized in muscle(s) or joint(s) 
and can include localized paresthesia and simple skin bends.  Type I symptoms can result in an 
EVA termination/abort and jeopardize mission success.  If not treated, Type I symptoms can 
eventually become incapacitating and jeopardize EVA crew-member recovery.  Type I 
incapacitating symptoms are generally preceded by less severe Type I symptoms. 
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Type II symptoms are systemic, generally neurological, involving the central nervous system, or 
cardiopulmonary, resulting in pulmonary “chokes”, circulatory collapse, shock, and even death; 
symptoms may also include multiple-site paresthesias.  Type II symptoms require immediate 
EVA termination and jeopardize both mission success and crew health.  Type II symptoms may 
or may not be preceded by Type I symptoms and may be life threatening, especially in the EVA 
environment if not abated by an increase in pressure and adjunctive treatment. 
 
Cutis Marmorata is a type of skin bends more serious than Type I skin bends where the skin has 
a marbled or mottled appearance.  It likely indicates that significant bubble formation is 
occurring throughout the body.  At JSC, this type of skin bends is categorized separately from 
Type I and Type II DCS.   
 
DCS is also associated with gas embolism (the presence of gas bubbles in the vascular system), 
both venous gas emboli (VGE) and arterial gas emboli (AGE). Although VGE can typically be 
filtered adequately by the lungs, circulating VGE is not a desired condition, especially with the 
presence of a patent foramen ovale (PFO), which is a hole in the wall separating the right and left 
atria of the heart.  A PFO is a remnant of life in the womb where oxygenated blood from the 
placental circulation is shunted away from the pulmonary circulation of the fetus.  This 
connection closes in most newborns, but approximately 25% of the adult population has some 
small patency (hole) that allows oxygenated and deoxygenated blood to mix.  If denitrogenation 
is not effective, either due to inadequate vehicle design (either in gas constituency or 
atmospheric pressure, or a combination of both) or inadequate operational PB protocols, the 
resulting presence of VGE during an EVA could cross through a patent PFO under particular 
conditions and become arterialized.  Many factors in the aerospace environment compromise 
healthy lung function. These factors, when combined with a high number of VGE entering the 
pulmonary circulation, can put astronauts at high risk for arterializing VGE that are normally 
filtered by a healthy lung.  AGE put the astronaut at risk for vascular blockages and resulting 
ischemic damage to the brain or other organs. 
 
Although the displacement of tissue by trapped gas spaces or the disruption of metabolic 
function due to embolic obstruction of blood flow can cause a wide range of signs and 
symptoms, the historical approach to DCS mitigation at NASA has been very conservative with 
the goal of preventing DCS.  One consistent observation concerning test subjects at the Johnson 
Space Center (JSC) is that pain-only DCS after significant denitrogenation is predominately 
found in the lower body, particularly associated in or around the patella (Degner et al. 1965, 
Ryles & Pilmanis 1996).   
 
B. Cause of DCS 
There are two conditions necessary for the development of DCS. The first condition is inert gas 
supersaturation, defined as a tissue inert gas partial pressure greater than ambient pressure. The 
second condition is the presence of a bubble nuclei (micronuclei) from which the supersaturated 
tissue inert gas can evolve into a gas bubble. 
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1. Supersaturation 
A fundamental axiom about DCS is that a transient gas supersaturation, also called over-pressure 
or pressure difference (ΔP), exists in a tissue region; the sum of all gas partial pressures in that 
region is greater than the ambient pressure opposing the release of the gas.  Expressed as an 
equation, supersaturation exists when ΔP is positive: 
                                                                                  
           n                         
ΔP = ∑  (Pi - P2)                              (Eq. 1)                                                                                                                                                                                         
         i = 1  
where Pi is the dissolved gas tension of the i
th
 gas of n species in the tissue and P2 is the ambient 
pressure after depressurization.  The potential for bubble nucleation and rate of bubble growth 
are a function of the supersaturation.  
 
Gas supersaturation in the tissue is not in itself harmful, but it is a thermodynamically unstable 
condition between the tissue and the surrounding environment.  The difference between tissue 
gas partial pressure and ambient pressure is easily resolved with a phase transition, and some of 
the excess mass (moles) of gas in the form of bubbles may be accommodated by the tissue and 
cause no symptoms.  However, whenever a gas space is formed due to partial or complete 
desaturation of a supersaturated tissue, there is some probability of DCS [P(DCS)] (Weathersby 
et al. 1984).  A necessary condition for DCS is the formation of a gas phase in the tissue.  The 
assumption that pain results from the deformation of tissue past a critical point due to evolved 
gas may not account for symptoms other than pain-only DCS, but evolved gas is certainly the 
primary insult for all subsequent signs and symptoms.  It is not the presence or even the volume 
of evolved gas in the tissue that is important in pain-only DCS, but rather the pressure difference 
between the gas space and the tissue.  The pressure difference was termed “deformation 
pressure” by Nims (1951). 
 
2. Bubble Nuclei (Micronuclei) 
The previous discussion focused on reducing the amount of tissue N2 to limit bubble growth, 
which is the classic Haldanean approach.  However, an emerging area of DCS prevention is to 
also hinder the transformation of tissue micronuclei into growing bubbles (Tikuisis & Gerth 
2003, Blatteau et al. 2006).  The presence of gaseous micronuclei in the tissues permits DCS 
under modest depressurizations (Weathersby et al. 1982).  Information about and evidence for 
tissue micronuclei come mostly from indirect observations.  The application of a high-pressure 
spike, either hydraulic or pneumatic, filtration, or ultracentrifugation of a sample are all accepted 
means by which to reduce the number and size of micronuclei (change the distribution), evident 
from fewer bubbles or cases of DCS after a subsequent depressurization (Evans & Walder 1969, 
Ikles 1970, Vann et al. 1980).  One inference from these studies is that normal activity 
establishes a size distribution of micronuclei within tissues, which can be modified by changing 
activity levels.  The idea of “using up” micronuclei faster than they are generated as a means to 
understand increased resistance to DCS due to repeated exposures has also been discussed (Hills 
1977).  A comprehensive review and discussion of micronuclei is not provided here, but 
information is available in Hills 1977, Hemmingsen 1989, Powell et al. 1993, 1995, Butler et al. 
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2006, Arieli et al. 2009, Hayward 1967, McDonough & Hemmingsen 1984, 1985, and Brubakk 
et al. 1989.   
 
C. Situations Resulting in DCS 
Humans are typically subjected to Earth-normal atmospheric pressure at sea level (1 ATA, 14.7 
psia, 101.3 kPa, 760 mmHg) and Earth-normal gravity (1 G).  This Earth-normal atmosphere is 
just one pressure in a range of higher and lower pressures where humans can comfortably exist.  
It is the rapid transition from higher to lower pressure that is the primary concern for DCS.    
 
1. Diving (Ascent from Depth) 
Long before humans could ascend to high altitudes, including space, they could dive to modest 
depths using compressed air or be exposed to modest depths through the application of caissons.  
Diving on compressed air or exposure to compressed air in a caisson allowed nitrogen (N2) to 
accumulate in tissues, based on the solubility of N2 in the tissues and the delivery of N2 by the 
circulatory system.  Ascent limits for these “non-saturation” exposures were empirically derived 
based on avoiding supersaturation of mathematically derived tissue half-time compartments.  
The type (depth and duration) of the dive defined the controlling half-time compartments to limit 
the supersaturation specific to the compartment.  Eventually, divers would remain long enough at 
an increased pressure to the point where no additional N2 would be absorbed by the tissues at the 
new saturation depth; these are called saturation exposures.  Ascents from saturation exposures 
are slower than those for non-saturation exposures because the total dissolved N2 is greater and 
the high N2 partial pressure has come into equilibrium in tissues with long half-times, which 
require longer times to denitrogenate during ascent back to 1 ATA. 
DCS is a known risk in the diving community and is mitigated through diver training and 
through the widespread use of decompression tables or dive computers, which determine dive 
time limits, ascent rates, and decompression stops. DCS due to diving is not the focus of this 
report. For a more detailed discussion on DCS due to diving and dive physiology, the reader is 
referred to references such as Bennett and Elliott’s Physiology and Medicine of Diving (Brubakk 
and Neuman, 2003). 
The focus of this evidence report is on preventing DCS during EVAs, but an EVA is just the 
culmination of many hours of training under both hyperbaric and hypobaric conditions. For ISS 
assembly EVAs, it was normal for a crewmember to train for EVA procedures in the JSC 
Neutral Buoyancy Laboratory (NBL) at a ratio normally exceeding 10 NBL hours per 1 EVA 
hour (Williams and Johnson, 2003).   
Policies and procedures are followed that minimize the P(DCS) after hyperbaric suited exposures 
in the NBL and the Russian Hydrolab during suited exposures in hypobaric chambers and after 
diving activities associated with the NASA Extreme Environment Mission Operations (NEEMO) 
underwater habitat.  For example, the objectives of an EVA are choreographed on flight-like 
hardware submerged in 40 feet of fresh water (FFW) at the NBL.  Training emulates actual EVA 
scenarios and can last for 6 hours.  To avoid DCS after long exposures to a maximum 
physiological depth of 50 FFW (pool depth plus suit pressure), astronauts breathe nitrox, a 
mixture of 46% O2 and 54% N2.  At this extreme, the equivalent air depth is 23 FFW.  Breathing 
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nitrox eliminates the need for staged depressurization at the end of a long training session, and 
some details about the NBL’s diving practices are available from Fitzpatrick & Conkin (2003). 
Astronauts also train and maintain proficiency in operating the spacesuit under hypobaric 
conditions in various altitude chambers at JSC.  In some cases, astronauts are required to fly in 
the T-38 aircraft or on commercial airlines shortly after a hyperbaric or hypobaric exposure.  
Specific directives, based on best available research (Horrigan et al. 1989, Vann et al. 1993, 
Pollock & Fitzpatrick 2004), dictate the proper surface intervals and PB procedures that 
minimize the P(DCS) in a subsequent hypobaric exposure.   
Procedures and equipment are available to treat DCS on orbit and after training activities, and a 
disposition policy (NASA JSC JPD 1800.2b) returns astronauts to flight status after a successful 
treatment regime.  Adherence to these policies and procedures, which undergo periodic review 
and updating, minimizes the probability that DCS will become a medical concern to the 
astronaut or will hinder the completion of training or safe execution of an EVA. 
2. Ascent to Altitude / Depressurization to EVA Suit Pressure 
A diver experiencing DCS will do so upon return to the surface after completing their dive; 
treatment in such circumstances typically begins almost immediately and requires little action on 
the part of the patient.  In contrast, an aviator that has lost cabin pressure or an astronaut during 
an EVA in a spacesuit could be afflicted with DCS during the performance of their tasks.  These 
tasks are left unfinished, and the aviator/astronaut must typically return themselves or be 
returned to a safe environment and configuration by a co-pilot or EVA partner before treatment 
for evolved gas can be initiated. Thus, in addition to the health risk associated with any 
occurrence of DCS, an occurrence of DCS during spaceflight carries the additional risk 
associated with delayed initiation of treatment as well as the secondary concern of the potential 
for loss of productivity. 
 
The most effective way to reduce P(DCS) is to reduce the ΔP between environments (described 
in Eq. 1) by reducing Pi (cabin inert gas [primarily N2] partial pressure), increasing P2 (suit 
pressure), or utilizing some combination of both to achieve acceptable risk and operational 
efficiency.  A spacesuit is a flexible spacecraft, and details about U.S. spacesuits are available 
from Thomas and McMann (2011).  The current NASA spacesuit, called the Extravehicular 
Mobility Unit (EMU), operates at 4.3 psia, or 222 mmHg, above the vacuum of space (Powell et 
al. 1994a, Locke 2008).  Current EMU suit technology, especially the design of the gloves, does 
not permit a high-pressure suit without causing increased fatigue, reduced mobility, and 
decreased manual dexterity, whereas the Russian Space Program accepts some of these human 
performance decrements and operates the Orlan suit at a pressure of 5.8 psia. Historically, 
reducing the risk of DCS by increasing the suit pressure has caused significant operational 
limitations, but developments are underway to develop a flight-ready variable-pressure suit 
capable of operating effectively between 3.7 and 8.3 psia.  
Risk of Decompression Sickness (DCS) 
 
 
10 
IV. Evidence 
A. Spaceflight Evidence 
Astronauts and cosmonauts working in spacesuits pressurized to between 3.7 and 5.8 psia have 
not reported DCS during EVAs.  In contrast, U.S. and Russian research subjects who evaluate 
operational PB protocols in altitude chambers report DCS at a rate of approximately 20% 
(Conkin et al. 2003).  How are these disparate observations reconciled? Technicians have 
reported pain-only DCS at JSC during suit development (two cases are documented in an internal 
NASA Investigation Report from 1988), and at least 1 astronaut recollected pain (after the 
spaceflight) in a knee on 2 occasions after depressurization to 5.0 psia in the spacecraft (Hawkins 
& Zieglschmid 1975).  Foster & Butler (2009) discussed several factors related to working in a 
hypobaric and µG environment that may reduce the P(DCS) in EVA astronauts, which are 
summarized in this section. 
    
1. Potential Bias to Not Report DCS Symptoms 
A research setting designed specifically to monitor for DCS is different from an operational 
setting where a highly trained and motivated crewmember is performing an EVA, which is 
considered one of the pinnacles of an astronaut’s career. Even if DCS symptoms have occurred, 
there may be a bias to not report mild discomfort in this type of operational setting, especially if 
symptoms are not limiting. NASA’s current policy is that every test subject and every 
crewmember who participates in hyperbaric or hypobaric operations is required to immediately 
report the onset of any DCS symptoms (NASA JSC JPD 1800.2b). 
 
Under-reporting of DCS symptoms is routinely observed in pilot training, where qualification to 
fly is compromised if DCS is reported during hypobaric training activities. This is discussed 
relative to the high-altitude U-2 pilot community (Bendrick et al. 1996 and Hundemer et al. 
2012), which highlights differences between operational and research reports of DCS.  
According to Bendrick et al. (1996), 75% of 273 active-duty and retired U-2 pilots responding to 
an anonymous questionnaire said that they had DCS symptoms at least once during their careers 
flying U-2 aircraft but rarely reported their symptoms to the flight surgeon (Meader 1967).  
Webb et al. 1996 reported a DCS incidence of 77% in subjects testing the 60-min U-2 PB 
protocol, which included mild exercise while at a simulated aircraft cabin pressure of 4.37 psia.  
Intense, short-duration exercise during this PB reduced the incidence to 42% in subjects and is 
offered to U-2 pilots who feel the need for additional DCS protection (Hankins et al. 2000).   
 
The only anecdotal report of a DCS symptom in an astronaut during spaceflight was reported 
several years after the flight in a personal autobiography rather than real-time to the flight 
surgeon (Hawkins & Zieglschmid 1975). For various reasons, astronauts and pilots are not 
motivated to report every small discomfort (Jersey et al. 2010).  As a result, it is possible that the 
first report of DCS during an EVA will be a serious case of DCS (Conkin 2001).  
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2. Masked DCS Symptoms 
There are various reasons why mild symptoms of DCS may be masked during an EVA.  Many 
astronauts take aspirin before an EVA, so mild aches and pains are managed in advance.  The 
EMU is a source of aches and pains of the same intensity as pain-only DCS.  As such, many mild 
cases of DCS that are not reported during an EVA could be attributed to pain caused by working 
in the EMU.  Because mild symptoms quickly clear during repressurization, astronauts would 
have little incentive to report a symptom that is no longer present after the EVA.  The incidence 
of DCS symptoms that would interfere with performance in an EMU was less than 5% in 
validation testing in altitude chambers (Waligora et al. 1984, Conkin et al. 1990).  
Approximately 85% of those with symptoms showed improvement in the symptom or showed no 
change in symptom intensity when tests were allowed to proceed past the point of the first 
symptom report.  Because PB protocols before EVA reduce the incidence and intensity of 
symptoms, it is understandable that any resulting mild symptoms are unremarkable in an 
operational setting.     
 
3. Operational and Gravitational Benefits of the Spaceflight Environment 
It is also possible that DCS has not actually occurred during an EVA (Powell et al. 1995, 
Gernhardt et al. 2004).  The situation of subjects wearing an O2 mask who are otherwise 
comfortable in a shirtsleeve environment at 1-G is not the same as that faced by astronauts 
surrounded by 100% O2 and maneuvering in µG with limited mobility and uncomfortable 
spacesuits.  Limited motion in the Orlan, and, by extrapolation, the EMU, is hypothesized to be a 
significant factor in reducing the likelihood of DCS during an EVA.  
 
Astronauts perform more conservative prebreathing in space than is tested on the ground, as 
ground-based PBs are performed in accordance with Aeromedical Flight Rules, and more than 
the minimum protection is always provided.  Based on a detailed analysis of actual PB episodes 
performed on-orbit, the tissue ratio (TR), or R-value, computed for the first 142 staged PB 
protocols from the Shuttle was 1.51 ± 0.07, compared with 1.52 ± 0.26 for 245 research subjects 
at JSC who had a DCS rate of 18% and who were ambulatory during testing (Conkin et al. 
2006).  Ambulation encourages DCS and VGE from the lower body, so the absence of 
ambulation in µG likely reduces the incidence of DCS below 18% during EVA (Conkin et al. 
2006).  During the Shuttle staged protocol, the TR also decreased during subsequent EVAs, from 
1.51 to 1.48 for the second EVA.  This is because breathing 100% O2 during a 6-hr EVA 
continues the denitrogenation process over multiple EVAs during a Shuttle mission, as well as 
because the crew lives at 10.2 psia / 26.5% O2, where tissues eventually equilibrate to a pN2 of 
approximately 7.5 psia.  Waligora & Pepper 1995 and Waligora & Kumar 1995 summarized 
physiological aspects of working in space during the first 59 Shuttle person-EVAs.   
 
In addition to added PB duration, we also need to understand if the primary risk mitigation 
strategy of prebreathing is more or less affected by adaptations to µG.  All astronauts undergo 
adaptation to µG (Nicogossian & Parker 1982).  Approximately 2 liters of fluid from the lower 
extremities is redistributed to the chest and head, with a resulting decrease in total body water.  
The upper body venous engorgement at the expense of a reduced lower body venous capacitance 
does not abate even after months in space, even following the net decrease in plasma volume.  
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As a result of this fluid shift, denitrogenation in µG may be more efficient than that on Earth if a 
supine body position is a reasonable analog for µG (Balldin 1973).   
 
Lesser interventions than adaptation to µG are known to modify N2 washout (Pendergast & 
Olszowaka 1989, Margaria & Sendroy 1950).  Jones et al. (1945) performed early work in 
understanding the effects of blood perfusion on N2 uptake and elimination in tissues.  Behnke et 
al. (1935, 1937, 1941) showed how body composition and exercise during PB influenced N2 
removal.  Studies by Balldin et al. (1971, 1972, 1973, 1978) showed how increased ambient 
temperature, supine body position, and immersion in water increased N2 removal from adipose 
and muscle tissue, as well as from the entire body.  Theis et al. (1979) confirmed and 
supplemented these data by examining whole-body N2 washout associated with the supine body 
position.  Balldin & Borgstrom (1977) and Curry & Lundgren (2003) reported that even 
negative-pressure breathing accelerates N2 washout.  The most recent efforts to understand N2 
removal under various experimental conditions, including µG simulation, were by Vann & Gerth 
(1995) and Gerth et al. (1987, 1989).  Various experimental interventions resulted in a wide 
range of tissue N2 washout from approximately 8 ml/kg for seated subjects to approximately 24 
ml/kg for subjects who performed 50 watts of continuous arm and leg exercise for 2 hr while at a 
6-degree head-down tilt during a 3-hr PB.  Thus, it is reasonable to hypothesize that the altered 
physiology and anatomy in response to µG adaptation modifies, in an unknown manner, the 
amount of N2 removed from the body during PB (Conkin et al. 1983, Powell et al. 1992, Conkin 
& Powell 2001). 
     
For a portion of any operational PB and all of an EVA, the astronaut is surrounded by 100%  
O2.  It is unclear how much N2 is transferred out of the body through the skin of astronauts or 
into the body of subjects surrounded by air in altitude chambers; however, any benefit would go 
to the astronaut (Groom & Farhi 1967).  A warm ambient temperature enhances denitrogenation 
(Balldin 1973).  Shuttle astronauts often reported that they were cool to cold during EVAs.  It is 
likely that research subjects are in a more comfortable thermal environment during a PB and 
EVA simulation than astronauts.  It is unclear how skin temperature that is cool due to the Liquid 
Cooling and Ventilation Garment affects the transport of N2 across the skin during the in-suit 
portion of the PB and during the EVA.  Conclusive knowledge regarding N2 washout in space or 
unbiased information from an in-suit Doppler bubble detector would greatly aid in understanding 
the true risk of DCS in EVA astronauts (Barer et al. 1995a, Conkin et al. 1996a, Conkin et al. 
1998, Thompson et al. 2002). 
 
Astronauts are physically active during PB, and exercise during PB accelerates N2 washout 
(Loftin et al. 1997, Webb et al. 1996, Pendergast et al. 2012).  Subjects in early trials at JSC 
were inactive during PB periods.  Aerobic fitness, as measured by VO2 peak, is not per se 
associated with resistance to pain-only DCS.  An analysis of VO2 peaks in subjects failed to 
show a strong association with DCS in exposures without PB and with resting PB.  However, the 
association was strong when exercise was included as part of the PB protocol (Conkin et al. 
2007, Pollock et al. 2004a).  The benefit of exceptional aerobic fitness in reducing the P(DCS) is 
only realized when exercise is exploited as part of the PB protocol.  A person with a low VO2 
peak can reduce their P(DCS) to match that of a fit person by increasing the intensity of exercise 
in the same PB time, increasing the length of the PB, or utilizing some combination of both 
(Conkin et al. 2007, Conkin et al. 2004).   
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Cumulative O2 consumption during PB is not the only consideration necessary for reducing the 
P(DCS).  Effective N2 elimination seems to depend on how the exercise is performed to a greater 
extent than just total O2 consumption per unit time normalized to body mass.  Additionally, there 
are constraints regarding the type and duration of exercise prescribed during the PB because a 
long EVA awaits the astronaut after the PB.  Women research subjects did not benefit to the 
same degree as men with respect to %VO2 peak when exercise during PB was prescribed 
(Conkin 2010).  Astronauts as a group are more physically fit than their age-matched research 
subject counterparts.  Current astronauts are approximately 10 years older than research subjects 
but have similar aerobic fitness as measured by VO2 peak.  Therefore, subjects who would be 
aged-matched to the astronaut population would be less fit.  If fitness is linked to DCS 
susceptibility (Webb et al. 2005, Carturan et al. 1999, 2002), then astronauts as a group under 
any PB condition may be less susceptible to DCS than subjects of a comparable age (Conkin et 
al. 2003).  Finally, the “effective” exercise in the EMU may be less than or different from 
exercise on Earth used to simulate EVA activity, and exercise is certainly an important 
consideration for DCS risk at altitude.  
 
4. Current ISS DCS Mitigation Strategies 
Different missions require different strategies to avoid DCS.  In every case, a detailed analysis 
(trade process) eventually defines the appropriate PB protocol.  We provide a summary of PB 
protocols that are currently in successful use, along with any lessons learned along the way. ISS 
astronauts currently have available three denitrogenation strategies to reduce the P(DCS): resting 
PB, staged denitrogenation, and exercise PB.   
 
The desire to perform science with µG as the primary variable led NASA to select an Earth-
normal atmosphere for the Shuttle and the ISS.  The Russian space program had already 
committed to an Earth-normal atmosphere, even before the Mir space station was launched.  A 
consequence of these decisions was that EVAs in the 4.3 psia EMU and the 5.8 psia Russian 
Orlan spacesuit could result in DCS, so efficient and effective denitrogenation protocols were 
needed.  Compounding the challenge is that an air break (brief exposure to high partial pressure 
of N2 (pN2)) during a 100% O2 PB is unavoidable if transitioning O2 delivery from a shirt-sleeve 
mask to the EVA suit. This issue requires research to understand and procedures to compensate 
for air breaks during PB.  
 
a. In-suit 4-hr Prebreathe 
In the simplest resting PB protocol, the astronaut breathes 100% O2 in the spacesuit for 4 hr.  The 
4-hr duration was determined as being necessary to achieve an acceptable P(DCS) based on the 
type and amount of work to be done in the suit and the duration of the hypobaric exposure 
(Conkin et al. 1987).  The operational challenge is to match the length of PB with an acceptable 
low incidence of DCS (Waligora et al. 1987) to produce an efficient EVA.  Waligora et al. 
(1984) described tests of 3.5- and 4-hr PBs at JSC, which evolved into the current operational 4-
hr in-suit PB.  The 4-hr in-suit PB has been used 6 times during spaceflight with no reported 
DCS. A 4-hr PB immediately prior to performing an EVA that could last up to 8 hr represents an 
inefficient use of crew time, makes the crew duty day over 14 hr on EVA days, and inefficiently 
uses up suit consumables.  
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b. Campout Protocol 
A modification of the Shuttle staged protocol, called the campout protocol, is now used on the 
ISS, which significantly reduces the required in-suit PB duration by having the two EVA 
crewmembers “camp out” in the ISS airlock at 10.2 psia, 26.5% O2 during the night prior to their 
EVA.  For various operational reasons, the time at 10.2 psia is limited to 8 hr and 40 min, most 
of which is spent sleeping.  The lack of food preparation and personal hygiene facilities in the 
airlock means that a post-sleep repressurization to 14.7 psia is required prior to suit donning. 
During this break, the 2 astronauts breathe 100% O2 by mask for 70 min while gathering food 
and using the restroom.  Upon return to 10.2 psia, 26.5% O2, the masks are removed, and the 
suit-donning process is completed.  The airlock is repressurized to 14.7 psia after the astronauts 
don their spacesuits to allow an assistant to exit at 14.7 psia and to complete the 50-min in-suit 
PB before the final depressurization of the airlock to the vacuum of space with the suits 
remaining at 4.3 psia.   
 
After extensive review, the similarity of the campout PB to the Shuttle staged PB (described in 
Section 4.5.1) along with good operational experience with the Shuttle staged protocol negated 
an empirical validation of the campout PB.  The first EVAs on the ISS using the campout 
protocol took place in September 2006, with approximately 145 person-EVAs completed by 
August 1, 2013.  
 
This more complicated staged PB protocol was favored over a simpler in-suit PB protocol.  The 
use of the staged protocol reduces fatigue in astronauts, who would otherwise be in the spacesuit 
for 10 to 12 hr, and increases the efficiency of the astronauts, as time that would otherwise be 
unproductive during a 4-hr in-suit PB can be spent on other tasks.  The only way to reduce 
fatigue and maintain efficiency while using the in-suit PB protocol is to perform the majority of 
the PB while using a mask outside of the suit,  but this eventually requires a transition from the 
mask to the suit.  Because the suit requires a 100% O2 purge and leak check, the transition from a 
mask, or even a mouth piece and nose clip, to the suit with 100% O2 without an air break has 
proven unavoidable. 
 
c. Exercise Prebreathe: CEVIS and ISLE Protocols 
After the ISS Quest airlock was delivered on STS-104.7A in July 2001 and before the campout 
protocol was available in September 2006, an option to perform exercise-enhanced 
denitrogenation from the ISS became available.  An accelerated denitrogenation protocol was 
needed to avoid scheduling constraints on EVAs performed from the ISS; additionally, because 
N2 elimination and uptake is a perfusion-limited process, the use of exercise during the PB is an 
effective method of accelerating denitrogenation.  The ambitious goal was to reduce the available 
4-hr resting in-suit PB by approximately 50%.   
 
Before the delivery of the Quest airlock, EVAs to support ISS construction were performed with 
hatches closed between the 2 vehicles so that the Shuttle 10.2-psia PB could be used.  The first 
use of the exercise PB protocol was to complete the installation of the ISS airlock.  The 
discomfort and complexity of adding an effective interval of exercise during PB must be 
balanced with the rewards, namely less total PB time and greater reduction in the P(DCS) from 
Risk of Decompression Sickness (DCS) 
 
 
15 
an alternative resting PB, or the option is not acceptable to the astronaut.  No single, reasonable, 
short-term intervention can increase cardiac output as much as exercise.  Exercise during PB was 
evaluated during and shortly after WW II (Behnke & Willmon 1941, Webb et al. 1943, Boothby 
et al. 1952) and reevaluated at Brooks Air Force Base (AFB) for the special operations 
community (Webb et al. 1989, 1996, 1998, 2002, 2004, Hankins et al. 2000) and, most recently, 
by NASA.  Details regarding approximately 9 exercise PB options evaluated by NASA from 
1997 to 2009 are available in the papers by Gernhardt et al. (2000, 2003), Conkin et al. (2004), 
and Loftin et al. (1997) (also see Table 3).  
 
Two exercise PB protocols acceptable for operations on the ISS are briefly described below: the 
Exercise PB protocol using the cycle ergometer with vibration isolation and stabilization 
(CEVIS) device and the In-suit Light Exercise (ISLE) PB protocol using the EMU as a resistive 
exercise device. 
   
Cycle Ergometer with Vibration Isolation and Stabilization (CEVIS) Protocol: 
For the CEVIS Exercise PB protocol, prior to launch, the astronaut performs a peak O2 
consumption (VO2) test using leg ergometry, and a linear regression of VO2 versus watts (work-
load) is created for that individual.  An exercise prescription is produced that distributes the 
appropriate work-load between the upper body (12%) and lower body (88%).   
 
During on-orbit EVA preparations, the astronaut breathes O2 from a mask and performs 3 min of 
incremental exercise on the CEVIS at approximately 75 revolutions/min using a prescription that 
increases the workload from 37.5% to 50.0% and then to 62.5% of their VO2 peak while also 
rhythmically pulling against elastic surgical tubing to include upper body activity.  The 
ergometry is complete after an additional 7 min at 75% of VO2 peak.   
 
After waiting an elapsed time of 50 min while still breathing 100% O2 from the mask, the EVA 
astronauts and the IVA crewmember depressurize in the ISS airlock to 10.2 psia over 30 min.  
During the depressurization period, the liquid cooling garment and the lower portion of the 
spacesuit are donned.  Once the airlock O2 concentration stabilizes at 26.5%, the astronauts and 
IVA crew attendant remove the masks and complete the donning of the upper torso of the 
spacesuit.  Thus, for a significant portion of the PB duration, the astronaut is physically active in 
the suit-donning process.  A leak check and then a purge with 100% O2 to remove N2 from the 
suit complete the suit-donning procedure.   
 
The in-suit PB starts in conjunction with a 5-min repressurization back to 14.7 psia, under which 
the remaining 55 min of the in-suit PB is performed and the IVA crewmember exits the airlock.  
The final depressurization of the airlock to the vacuum of space and to 4.3 psia in the suit takes 
30 min. The CEVIS Exercise PB has been used 50 times as of 08/01/13 with no reported DCS. 
 
In-Suit Light Exercise (ISLE) Protocol: 
For the ISLE PB protocol, the astronaut does not perform a short bout of intense PB exercise on 
the CEVIS prior to suit donning at 10.2 psia but instead performs a longer period of mild 
exercise in the EMU.  The ISLE protocol shares many steps with the Exercise PB protocol but 
differs in that 40 min are spent breathing 100% O2 by mask followed by a 20-min 
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depressurization to 10.2 psia.  Once suit donning is complete, arm and leg motions are performed 
for 4 min, followed by 1 min of rest in conjunction with a 5-min repressurization back to 14.7 
psia.  The mild exercise pattern continues for 50 min and achieves a minimum VO2 of 6.8 
ml*Kg-1*min-1.  An additional 50 min of resting PB completes the protocol, followed by a 30-min 
depressurization of the airlock to vacuum. The ISLE PB has been used 16 times as of 08/01/13 
with no reported DCS. 
 
Combining Exercise with Intermittent Recompression: 
The return to 14.7 psia after a short suit donning period at 10.2 psia in both the Exercise and 
ISLE PB protocols, as well as the 2 returns to 14.7 psia over the course of the longer campout 
PB, likely reduced the subsequent P(DCS) through removal of silent bubbles.  These bubbles had 
the potential to form from a limited number of large-radius micronuclei during the initial 
depressurization to 10.2 psia.  Once formed and then reabsorbed during the repressurization to 
14.7 psia while breathing 100% O2, the tissues are temporarily left with micronuclei with a 
smaller range of radii from which bubbles can be formed during the final depressurization to 4.3 
psia.  This did not occur during the Shuttle 10.2 psia staged depressurization protocol.  The entire 
habitable volume of the Shuttle was depressurized, so the astronauts simply continued the 
depressurization from 10.2 to 4.3 psia after suit donning in the airlock. 
 
5. Retired Prebreathe Protocols 
The remainder of this section is a brief historical summary of PB protocols that were successful, 
with lessons learned along the way. 
  
a. Shuttle Staged Protocol 
In the Shuttle staged denitrogenation strategy, the ambient pressure was decreased to an 
intermediate pressure so that the inspired partial pressure of N2 (PIN2) was lower than the initial 
PIN2 (Allen et al. 1969, Maio et al. 1970, Cooke & Robertson 1974, Horrigan & Waligora 1980, 
Waligora et al. 1983).  The staged depressurization approach is enhanced when O2 concentration 
is also increased to lessen the impact of hypoxia and to further reduce PIN2.  However, the initial 
pressure reduction could transform a subpopulation of tissue micronuclei into “silent” bubbles, 
so a 60-min PB with a mask was performed before the initial modest reduction in ambient 
pressure to 10.2 psia (Damato et al. 1963, Degner et al. 1965, Vann & Torre-Bueno 1984, 
Waligora et al. 1984, Hills 1985).   
 
This protocol that ultimately became the preferred PB for the Shuttle was achieved in 3 steps:   
1. Initial 60-min PB by mask, 45 min of which was completed before the Shuttle 
atmosphere was depressurized from 14.7 to 10.2 psia and the air was enriched to 26.5% 
O2 to provide an inspired partial pressure of O2 (PIO2) of 127 mmHg.  
2. Minimum stay of 12 hr at this intermediate pressure. 
3. In-suit PB before a final depressurization to 4.3 psia, lasting 40 to 75 min depending on 
the time spent at 10.2 psia. 
 
Figure 1 shows the cumulative fraction of VGE first detected in subjects exposed to 4.3 psia for 
4 hr after 3 different PBs.  A related figure appears in Waligora et al. (1984) (their Figure 12).  
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All subjects performed EVA-simulation work activities and were ambulatory at 4.3 psia.  The 
solid line that increases (steps) and plateaus quickly to approximately 45% is derived from data 
from 10 of 22 subjects that had VGE with a mean onset time of 43 ± 43 min.  This trial did not 
include a 1-hr PB before a 12-hr stay at 10.2 psia where subjects breathed 26.5% O2.  The dashed 
line that plateaus to approximately 50% VGE is derived from the same trial as described above 
except that it did include a 1-hr PB before the ascent to 10.2 psia.  The mean VGE onset time in 
18 of 35 subjects with VGE was 105 ± 48 min.  Finally, the dashed line that plateaus to 
approximately 65% VGE was derived from a trial with a 3.5-hr PB and a direct ascent to 4.3 
psia.  The mean VGE onset time in 15 of 23 subjects with VGE was 115 ± 55 min.  The mean 
VGE onset times were significantly longer (p<0.002) compared with the times from the trial 
without the 1-hr PB before ascent to 10.2 psia for 12 hr. 
 
Figure 1. The onset time for the first detection of VGE was earlier in a trial (Test 2b) where no 
PB was performed before the first ascent and subsequent 12-hr exposure to 10.2 psia (solid line) 
compared with the onset time when a 1-hr PB was performed (50% peak, Test 3b) or when there 
was a direct ascent to 4.3 psia after a 3.5-hr PB (65% peak, Test 2a).  Data for Test 3b are from 4 
hr of a 6-hr exposure.       
 
The computed decompression dose (described later) was slightly higher in the trial that omitted 
the initial 1-hr PB, so a high group incidence of VGE was expected.  Instead, a rapid onset of 
VGE was observed in a few subjects, possibly because micronuclei associated with the vascular 
endothelium transformed into silent bubbles ready to grow and enter the venous circulation after 
the final depressurization to 4.3 psia.  An ascent to only 10.2 psia (3,000 m, 9,750 ft) without 
utilizing a PB protocol predisposed some subjects to produce VGE shortly after reaching 4.3 
psia, even after spending 12 hr at 10.2 psia, with a 40-min PB before the final ascent to 4.3 psia.  
It is notable that in 5 of the 10 subjects in this trial, VGE was first detected within 30 min at 4.3 
psia.  VGE was detected in 1 subject after 1 min at 4.3 psia, and the subject had signs and 
symptoms classified as serious DCS at 65 min.  DCS was diagnosed in all 3 trials, with a group 
incidence of approximately 20% and a mean onset time to first symptoms of approximately 2 hr.   
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Optimization of the final Shuttle 10.2-psia staged depressurization protocol took months of 
planning and years of validation.  The first critical step was to certify the Shuttle for operations at 
a reduced pressure with an enriched O2 atmosphere, as the vehicle was not planned to operate 
under these conditions.  Several interacting variables were evaluated in isolation or in 
combination: rate of ascent to intermediate pressure, the intermediate pressure itself (equipment 
cooling issues, Horrigan et al. 1985), the pO2 and pN2 at the intermediate pressure (hypoxia and 
flammability issues, Waligora et al. 1982), length of stay (Damato et al. 1963, Waligora et al. 
1983), likelihood of silent bubbles, final suit pressure, duration of EVA, work performed in the 
suit, final in-suit PB time before final ascent, and balancing the acceptable risk of DCS during 
EVA with limited treatment options (Adams et al. 1981, Waligora et al. 1984). 
 
The time at 10.2 psia and 26.5% O2 did not constitute a break in PB because the lengthy 
exposure to a reduced pN2 at approximately 7.5 psia continued the denitrogenation process.  
Astronauts simply donned their suits at 10.2 psia when they were ready and performed a final 
40- to 75-min in-suit PB before final depressurization to 4.3 psia, without the need to first 
repressurize to 14.7 psia.  If the time spent at 10.2 psia was expected to be greater than 36 hr, the 
initial 60-min mask PB at 14.7 psia was omitted.  The rationale for this was that any silent 
bubbles formed during the 15- to 20-min depressurization to 10.2 psia would be reabsorbed 
given enough time at 10.2 psia.  Although this procedure was complicated and had several 
operational and physiological impacts, it was preferred over the simpler but less efficient 4-hr in-
suit PB protocol.  The first EVAs that used the Shuttle staged protocol were on STS-41B in 
February 1984, and the last of the 153 person-EVAs was in 2011 with the retirement of the 
Shuttle. 
 
b. Skylab 
Skylab provided a unique environment in which to conduct studies on adaptation to µG.  The 
atmosphere for Skylab achieved a working balance between risk and reward.  The science and 
medical community accepted an atmosphere of 70% O2 at 5.0 psia because the Earth-equivalent 
PIO2 would be 150 mmHg, and the risk of atelectasis was minimized because the atmosphere 
was 30% N2.  Scientists on Earth did not have to provide a hypoxic or hyperoxic environment as 
part of their ground-based control studies, so µG was the primary experimental variable.  No 
dedicated PB was needed before EVAs from Skylab in spacesuits pressurized to 3.7 psia because 
the tissues would eventually equilibrate to a computed tissue N2 partial pressure (P1N2) of no 
more than 1.2 psia, far below the suit pressure.  Various restrictions, such as uncomfortable 
flame-retardant polybenzimidazole clothing, were imposed due to the serious risk of fire in a 
70% O2 atmosphere.  However, Skylab was a success, and the need to confront several technical 
issues early in the mission showed that an effective EVA capability was critical to the success of 
long-duration missions.   
c. Apollo and Gemini 
A minimum 3-hr in-suit PB was performed before launch in all NASA programs prior to the 
Shuttle (Maio et al. 1970).  This protocol protected inactive astronauts from DCS after reaching 
orbit; during ascent, the cabin pressure was reduced from 14.7 psia to 5.0 psia, and the 
atmosphere was simultaneously enriched to 100% O2 (Powell et al. 1994a).  Although this PB 
was effective in most cases, 1 astronaut wrote, years after leaving the space program, that he had 
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symptoms consistent with DCS while at 5.0 psia.  Michael Collins, during Gemini X and later 
during Apollo 11, believed he had symptoms of pain-only DCS in his left knee that eventually 
resolved in the 100% O2 atmosphere as the missions proceeded (Hawkins & Zieglschmid 1975).  
This was not an unexpected outcome based on previous PB validation trials reported by Maio et 
al. (1969, 1970).  Astronauts on subsequent EVAs from the Apollo spacecraft and Skylab, as 
well as on moon walks from the Lunar Module, in suits pressurized to 3.7 psia were not at risk 
for DCS due to denitrogenation during their extended time in the hypobaric and hyperoxic 
breathing environment.  
6. DCS Modeling Evidence 
Probability models are critical to the understanding and mitigation of DCS risk. These models 
are first developed as statistical descriptions of DCS incidence from a given data set and 
eventually predict DCS incidence effectively over a given boundary of input parameters. Certain 
DCS models will be described in this section, and Appendix A is provided for a comprehensive 
summary of DCS model details. Models are typically used to develop potential PB protocols, 
which are then tested on the ground in hypobaric EVA simulations to ensure that the protocol 
achieves acceptable DCS risk level. DCS models assess impacts to ground-validated protocols, 
which are often modified during the transition from research to operations. In these cases, the 
models are used to ensure that changes to the validation protocol are neutral or in favor of 
enhanced crew safety. In some cases, DCS probability models, in conjunction with expert 
opinion, have been used in place of ground testing to accept a PB protocol, which was the case 
with the Campout PB.   
 
In addition to statistically driven probability models, a decompression dose can also be computed 
from a biophysical model of bubble growth, such as the maximum size a theoretical bubble can 
achieve, the rate of growth of the bubble, and the summed volume from a collection of bubbles 
competing for inert gas (Tikuisis & Gerth 2003, Srinivasan et al. 2003).   
 
a. Tissue Ratio 
Fundamental to understanding the P(DCS) in astronauts is to first understand how a tissue ratio 
(TR) is calculated.  The TR is a simple index of decompression dose, first used by Haldane to 
define the limit to direct ascent for divers at the end of the 19th century.  The reader is referred to 
Stepanek & Webb (2008) for the historical background on the TR.   
 
The TR is the ratio of the computed P1N2 in a theoretical tissue to ambient pressure.  Equation 2 
defines P1N2, and P2 is the ambient pressure after depressurization. Prebreathing 100% O2 or 
O2-enriched mixtures before a hypobaric exposure reduces P(DCS), so it is necessary to account 
for the use of O2-enriched mixtures as part of the expression for decompression dose.  After pN2 
in the breathing mixture changes, such as during a switch from ambient air to a mask supplied 
with 100% O2, the pN2 that is reached in a designated tissue compartment after a specific time is 
P1N2:  
  
P1N2 = P0 + (Pa – P0) (1 - e - k t ),          (2) 
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where P1N2 is calculated for the tissue after t min, P0 is the initial pN2 in the compartment, Pa is 
the ambient pN2 in the breathing mixture, and t is the time at the new Pa in min.  The tissue rate 
constant k is equal to ln(2) / t1/2, where t1/2 is the half-time for pN2 in the 360-min compartment.  
The particular half-time compartment is a statistical construct that optimizes TR as a 
decompression dose based on the observed dichotomous DCS or VGE outcomes from a 
collection of trials (Vann et al. 1987).  Different half-time compartments reflect the varying rates 
at which different body tissues take up and eliminate inert gases.  For example, fast 5- and 10-
min half-time compartments are used to represent the brain and spinal cord, which are highly 
perfused and rapidly take-up and eliminate inert gases.  A long 360-min half-time is associated 
with long PB times as tested by NASA (Conkin et al. 1996).  A shorter half-time combined with 
long PBs produce low TRs that are not consistent (optimized) with trials that yield significant 
DCS and VGE incidence.  The half-time compartment is simply a surrogate linked to the actual 
process at the tissue level that dictates the true evolved gas condition.  
 
Equation 3 describes the simple case where Pa changes instantaneously, a step-change.  This 
form is sufficient in most applications since donning or removing an O2 mask changes Pa within 
a few breaths.  There is also the possibility that Pa changes over time, such as by breathing air 
during a long depressurization or by changing the N2 content over time at some intermediate 
pressure.  An expanded form of Eq. 3 covers these cases.  One novel application is to reduce N2 
content over time as dictated by the operational time-line such that P1N2 is appropriate at the 
time of suit donning, thus avoiding a final in-suit PB period.  This application requires an 
automated control system to change the breathing atmosphere over time and space within a 
vehicle that is compatible with enriched O2.  The cost likely exceeds the rewards with this 
approach, so it has not been pursued.  Finally, Eq. 2 is modified to compute P1N2 to account for 
intervals of exercise during PB.  The tissue rate constant k is defined in terms of %VO2 peak 
during the PB (Conkin et al. 2004).     
 
Equation 3 is one form of the TR as the decompression dose, which approximates the potential 
volume at an ambient pressure of N2 evolved in a unit volume of tissue given that all the 
available N2 at P2 has transformed from the dissolved state to the evolved state (Conkin 1994, 
Conkin et al. 1998):    
 
decompression dose = [(P1N2 / P2) – 0.79],        (3) 
 
where decompression dose is 0 at sea level because [(11.6 / 14.7) – 0.79] is 0.   
 
The TR is an index of the true decompression dose and is fundamental to other formal 
expressions of decompression dose as evolved gas.  Given an abundance of quality research data, 
the bottom of the S-shaped curve on a DCS versus TR dose-response curve would be nearly flat 
over a range of TRs to approximately 1.1.  The flat region is an indication that decompression 
dose must exceed some critical value.  The TR is utilitarian and easy to use in statistical 
regression models to describe DCS and VGE outcomes from combined research trials over a 
range of TRs.  TR, or R-value in NASA terminology, becomes a number that cannot be 
exceeded.  For example, an R-value of 1.65 or less is acceptable for EVA operations in the 4.3 
psia EMU from the Shuttle, but this R-value of 1.65 in an EMU does not mean the P(DCS) is 
zero (Conkin et al. 1990, Kumar & Powell 1994).   
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Risk and reward must be balanced to achieve an operational protocol, and finding this balance is 
as much an art as a science.  Operations using the Russian Orlan spacesuit at 5.8 psia result in an 
R-value of approximately 1.85 to provide a P(DCS) that is the equivalent of the P(DCS) in the 
EMU; thus, the acceptable R-value (TR) is not an absolute, but is a function of the suit pressure 
(Conkin et al. 1996, Chadov et al. 1996).  The DCS research and operational EVA experience in 
the Russian space program is too extensive to summarize here (Barer 1995a) and parallels the 
efforts in the U.S. space program. 
 
b. Statistical and Biophysical Models 
Statistical descriptions of DCS and VGE outcomes from hypobaric exposures using logistic 
regression and survival analysis and biophysical modeling of tissue bubble dynamics have both 
made significant advances in the last 20 years.  The integration of both approaches has produced 
sophisticated probabilistic models, which are briefly summarized here.  Probabilistic modeling 
requires four items: (1) a data set that contains a dichotomous response variable, i.e., the 
presence or absence of DCS, and one or more explanatory variables; (2) an expression of 
decompression dose in terms of explanatory variables; (3) a function, such as the logistic 
function or Hill equation, which structures the dose model so that the outcome is a calculated 
P(DCS); and (4) a parameter-estimation routine on a computer that uses maximum likelihood.   
 
Simple descriptions of decompression dose, such as TR or ΔP, approximate the true dose 
(Weathersby & Homer 1984, Conkin 1994), whereas models about tissue bubble dynamics strive 
to define the true dose through diffusion-based physics and consideration of mass-balance 
(Epstein & Plesset 1950, Van Liew & Hlastala 1969, Gernhardt 1991, and more recently Gerth & 
Vann 1997, Thalmann et al. 1997, Srinivasan et al. 2002, 2003, and Nikolayev 2008).  These 
referenced models, as well as many others, contribute to a single evolving model that describes 
the P(DCS) in both diving and altitude depressurizations by invoking multiple tissue 
compartments, multiple finitely diffusible gases, and a distribution of bubble nuclei that begin to 
grow at different times during depressurization.  Other researchers have concentrated just on 
hypobaric depressurizations (Foster et al. 2000a,b, Kumar et al. 1992, Kumar & Powell 1994, 
Conkin et al. 1996, Pilmanis et al. 2004, Thompson et al. 2003).  Recent advances in 
probabilistic modeling came through the use of techniques from survival analysis.  Weathersby 
& Gerth (2002) and Tikuisis & Gerth (2003) provided additional details about probabilistic DCS 
modeling. 
  
Tissue Bubble Dynamics Model (TBDM): 
The TBDM is a biophysical model of bubble growth in tissue (Gernhardt 1991) that has been 
used in the development of decompression protocols for more than 25,000 commercial dives and 
used by NASA in the development of EVA prebreathe protocols (Gernhardt 2008).  In the 
model, assumed fixed values for several parameters, such as the blood-tissue N2 partition 
coefficient, initial radius of micronuclei, N2 diffusivity between a tissue and bubble, surface 
tension on a spherical bubble, and tissue bulk modulus, are used to describe the mass balance of 
tissue and bubble gases for a single growing bubble in a unit volume of tissue (details in Figure 
2).  
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When inputted with the relevant durations, rates, pressures, and gas compositions, the TBDM 
generates an output called the bubble growth index (BGI), which is the time-varying ratio of 
bubble radius to an initial 3-µm radius of the bubble nucleus. The BGI for a decompression 
exposure is calculated over the duration of the exposure, with the peak BGI value typically being 
used as the primary measure of decompression stress. Although the TBDM accommodates 
modeling of multiple half-time compartments to reflect the varying rates at which different body 
tissues take up and eliminate inert gases, the model typically includes only a 360-min theoretical 
half-time for tissue N2 kinetics when it is used to estimate decompression stress during EVAs.  
 
 
Figure 2. Tissue Bubble Dynamic Model equation and parameters 
 
A statistical analysis of 6437 laboratory dives (430 DCS cases) compared predictions of the 
TBDM with the Workman M-value and the Hempleman PrT index, with TBDM predictions 
(BGI) yielding the best log-likelihood and Hosmer-Lemeshow (H-L) goodness-of-fit test results 
(Gernhardt 1991). BGI also provided significant predictive ability (p < 0.01) and goodness-of-fit 
for DCS (H-L p=0.35) and VGE (H-L p=0.55) data based on 345 altitude decompression 
exposures (57 DCS cases, 16.5% DCS, 41.4% VGE), including prebreathe staged 
decompressions, all with exercise at altitude and including data points at 10.2, 6.0, and 4.3 psia 
(Abercromby et al. 2008).  
 
c. Modeling and Operations 
One reasonable expectation from modeling is that fewer trials, or even no trials, are performed 
before accepting a variation of a tested protocol if the model computes an acceptable P(DCS), 
P(serious DCS), or even P(Grade IV VGE).  This was the case in a recent decision to accept the 
campout PB for ISS without direct testing of this variant of the Shuttle 10.2 psia staged PB 
(Gernhardt 2008).  Aside from increasing computational efficiency for complex models, 
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probabilistic modeling will significantly advance when the link is quantified between evolved 
gas in tissue and the perception of pain by the central nervous system (Conkin et al. 1998).  An 
assumption in modeling is that the outcome variable is known with certainty, which is not the 
case (Weathersby et al. 1984, Freiberger et al. 2004, Conkin et al. 2006), and adds an additional 
level of uncertainty to probabilistic modeling. 
 
 
Table 1 shows the DCS incidence from PB protocol ground validation trials compared with the 
flight DCS incidence and the modeling predictions that take into account the operational changes 
from the ground trial protocol to the in-flight operational PB protocol (Conkin & Powell 2001).  
Accepting a new PB protocol without prior ground testing validation is rare, but the ISS campout 
protocol was accepted in 2005 based on empirical evidence and modeling analysis.  It has been 
successfully used from ISS to support over 145 person-EVAs to date.   
 
Table 1. Observed and model-estimated probability of DCS for NASA prebreathe protocols as 
of August 1, 2013. 
Prebreathe 
Option 
Ground 
Trial 
Subjects 
Tested 
Ground Trial 
DCS 
Incidence 
(95% CL*) 
Model 
Prediction† 
P(DCS) 
(95% CI**) 
EVAs 
using PB 
Option 
Flight DCS 
Incidence 
(95% CL*)  
4-hr In-Suit 28 21.40% 4.60% 4 0% (9.8-38.0%) (2.2-9.4%) (0.0-60.0%) 
Campout -- -- 2.80% 145 0% (1.2-5.9%) (0.0-2.7%) 
CEVIS 45 0% 2.00% 48 0% (0.0-6.5%) (0.4-9.2%) (0.0-9.2%) 
ISLE 47 
4.20% 0.30% 
16 
0% 
(0.7-12.8%) (0.01-6.3%††) No 95% CL calculated 
*From binomial distribution – one-sided 95% CL 
**From regression models that provide 95% CI 
†Model predictions include operational prebreathe margin and effects of microgravity.  
††Based on option 1 operational prebreathe given a nominal value of 6.8 ml/kg/min. 
 
Existing models can only be extrapolated to the Exploration Atmosphere environment because 
the data underlying the model assumptions are based on depressurizations from 14.7 psia. An 
example of the application of probabilistic DCS models is provided in Table 2.  The simulations 
for final in-suit PB times are based on an assumption of equilibrating to an atmosphere of 8.0 
psia with 32% O2 prior to the final in-suit PB. Even with the recent recommendation to adjust to 
8.2 psia with 34% O2, the partial pressure of N2 remains the same; therefore, the computed 
P(DCS) would not change (Norcross et al. 2013).    
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Table 2. Examples of model-estimated P(DCS) for a simulated lunar mission.* 
P1N2 PB 
(min) 
TR P(DCS) 
(95% CI)  
P(VGE) P(GIVVGE) P(serious 
DCS) 
5.57 0 1.29 0.13 
(0-0.30) 
0.20 0.19 0.003 
5.57 22 1.25 0.099 
(0-0.26) 
0.15 0.16 0.002 
5.44 0 1.26 0.10 
(0-0.27) 
0.17 0.17 0.003 
5.44 22 1.22 0.082 
(0-0.21) 
0.13 0.14 0.002 
5.44 30 1.19 0.06 
(0-0.18) 
0.10 0.12 0.0017 
Reference Conkin et al. 1996 
Conkin 
et al. 1990 
# Conkin 
2001 
* All estimates are extrapolations from statistical models. 
Results based on 8-hr EVA with equivalent 1-G ambulation and mild exercise. 
EVA after equilibration to 8.0 psia with 32% O2. 
# unpublished Grade IV VGE regression from Conkin, n = 549 NASA records. 
 
 
B. Ground-based Evidence 
Validation testing often precedes the implementation of a PB protocol in space operations.  The 
first test of several PB protocols was in August 1982, with DCS reported after a 3.5-hr PB in one 
subject and a Doppler technician (Conkin et al. 1990, 2003).  This was an inauspicious start to 
the validation of a 3.5-hr PB.  A 4-hr PB reduced the incidence of DCS from 42% to 21% and 
reduced the incidence of VGE from 71% to 46% based on data normalized to a 6-hr exposure to 
4.3 psia in men who ambulated as part of their exercise at 4.3 psia (Waligora et al. 1984, Conkin 
et al. 1990).  On April 12, 1981, the Shuttle STS became a reality.  The first EVA from the 
Shuttle was on April 7, 1983, using a 3.5-hr baseline in-suit PB.  Only 3 two-person EVAs have 
been performed from the Shuttle after a 3.5- or 4-hr in-suit PB since April 1983.  The 4-hr in-suit 
PB remained an option throughout the Shuttle program and remains on option on ISS.   
 
The inefficiency of an in-suit PB and the possibility of a break in PB during the transition from 
an O2 mask to the spacesuit required that NASA validate the staged 10.2 psia protocol in the 
early 1980s.  Variations of similar protocols soon emerged, along with a desire to summarize all 
the results with a simple decompression dose.  In addition to the DCS outcomes, routine 
ultrasound bubble monitoring provided an unbiased assessment of the decompression dose.  The 
Spencer 0 – IV categorical scale (Spencer 1976, Neuman et al. 1976) was adopted, and the 
following standard 4-min evaluation scheme to improve bubble detection and grading was 
implemented at JSC (Adams et al. 1979):  a Doppler technician located and optimized an 
acceptable Doppler ultrasound blood flow signal in the pulmonary artery from a sitting or semi-
recumbent subject in an altitude chamber in approximately 15 sec.  The subject was then 
instructed to rhythmically flex each limb three times in sequence, moving all joints in the limb.  
The movement dislodged small bubbles sequestered in venous capillaries, and the grade of VGE 
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passing beneath a 5.0- or 2.5-mHz ultrasound wave was assigned by an investigator outside the 
altitude chamber.   
 
Figure 3 illustrates decompression dose-response curves for DCS and VGE outcomes from 341 
exposures to 4.3 psia in altitude chambers at JSC.  These subjects breathed 100% O2 through a 
mask and were otherwise in a comfortable shirtsleeve environment.  The mean exposure time 
was 4.4 ± 1.3 hr, and subjects ambulated from one exercise station to another.  Exercise included 
cranking and pulling against modest resistance, as well as torquing fixtures to simulate the type 
and intensity of work performed during a contingency EVA; details are provided in Conkin et al. 
(2003).  At intervals of approximately 15 min, the pulmonary artery was insonated with an 
ultrasound bubble detector in recumbent subjects.  Given enough exposures over a range of 
decompression doses, a predictive equation for DCS and VGE was created, in this case from the 
Hill equation.  The wide 95% confidence limits for DCS and VGE suggest that factors other than 
simple decompression dose influence the outcome.  There is more to accepting a denitrogenation 
protocol than just the raw incidence of DCS or VGE.  The nature of the symptoms, how the 
incidence of DCS is related to the intensity of the symptoms (Allen et al. 1971), and the response 
of individuals to repressurization (Krause & Pilmanis 2000) are as important as the overall 
incidence of DCS and VGE to a final decision to accept a protocol. 
 
Figure 3.  P(DCS) and P(VGE) increase as decompression dose increases.  The 95% confidence 
limits (shorter curves) above and below the best estimate help to visualize uncertainty in the 
outcome. 
Table 3 summarizes DCS and VGE results archived at JSC in the NASA Hypobaric 
Decompression Sickness Database.  Tests conducted for NASA by Brooks Air Force Base 
(AFB) are not shown here but are available in the Air Force Research Laboratory Altitude 
Decompression Sickness Research Database archived at Wright-Patterson AFB and available 
through their website.   Operational questions dictated the sequence of testing in Table 3.  The 
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first trials evaluated the 3.5- (Tests 1a and 2a) and then 4-hr in-suit PBs (Tests 3a and 3c), and 
the subjects in these protocols often “crossed over” to validate the 10.2 psia staged PBs.  Several 
variations of the staged protocol tested the benefit of an initial 60-min PB before ascent to 10.2 
psia, different durations at 10.2 psia, and different final in-suit PB times before depressurization 
to 4.3 psia (Tests 1b, 1c, 1d, 2b, 3b, 3d).  Repetitive exposures to 4.3 psia while living at 10.2 
psia addressed issues of fatigue and cumulative DCS and VGE risk (Tests 4a through 4f).  
Cumulative risk was found not to be a concern in repetitive hypobaric depressurizations (Cooke 
et al. 1975, Conkin et al. 1990, Pilmanis et al. 2002), so repetitive EVAs from the Shuttle were 
deemed safe.  Women were first used at JSC in a trial of a 6-hr PB (Test 5a) and in a novel 10.2-
psia staged protocol where the simulated suit pressure was 6.0 psia with 60% O2.  A trial of an 8-
hr resting PB (Test 5b) established the benefits of extreme prebreathing, even if not practical 
from an operational perspective.  The influence of high work rate during EVA was evaluated 
using a row machine (Maio et al. 1970), resulting in two cases being classified as serious DCS in 
subjects from Test 7a.  Exercise intended to counteract deconditioning in space did not influence 
the subsequent DCS and VGE outcome given that the interval between the exercise and 
simulated EVA was 16 hr (Tests 8a and 8b; Kumar et al. 1992).  The consequences of 
ambulation before and during an altitude exposure were evaluated at both 6.5 and 4.3 psia in the 
Argo series, starting with Test 9a and ending with Test 11a.  Test 9a included ambulatory 
controls, and Test 9b included the same subjects but at 6-degree head-down bed rest for 3 days 
before and during the 3-hr exposure to 6.5 psia without prior PB.  The incidence of Grade III 
plus IV VGE was lower in the bed rest group, and it took longer before Grades III and IV VGE 
were first detected (Kumar et al. 1993a).  Astronauts sometimes fly in commercial airliners or fly 
a T-38 jet shortly after training in the NBL.  Test 10 included a hyperbaric and then a hypobaric 
exposure to evaluate the consequences of flying after diving under our specific training 
conditions.   
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Table 3. Summary of DCS and VGE in tests conducted from 1982-2009. 
Test P2 
(psia) 
Conditions* Number 
m       f 
Mean 
age 
(years) 
DCS VGE 
(any grade) 
VGE  
(Grade IV) 
1a 4.3 P 11      0 34.5 4 7 4 
1b 4.3 S 13      0 32.3 3 11 7 
1c 4.3 S 12      0 32.0 4 7 6 
1d 4.3 S 3      0 39.6 2 3 2 
2a 4.3 P 23      0 31.6 7 15 8 
2b 4.3 S 22      0 31.5   6† 10 7 
3a 4.3 P 28      0 31.0 6 13 11 
3b 4.3 P,S 35      0 30.1 8 20 8 
3c 4.3 P 14      0 32.5 3 5 1 
3d 4.3 P,S 12      0 28.5 2 5 2 
4a 4.3 P,S 12      0 30.1 1 7 3 
4b 4.3 P,S 12      0 30.1 0 2 1 
4c 4.3 P,S 12      0 30.1 0 4 1 
4d 4.3 P,S 12      0 30.1 0 0 0 
4e 4.3 P,S 12      0 30.1 0 4 1 
4f 4.3 P,S 12      0 30.1 0 0 0 
5a 4.3 P 19      19 31.5 4 11 4 
5b 4.3 P 11      0 32.0 0 0 0 
6 6.0 S 15      14 32.9 1 3 0 
7a 6.5 direct ascent 11      0 28.2     4†† 8 6 
7b 6.5 direct ascent 11      0 28.2 2 8 4 
8a 6.5 direct ascent 29      11 32.5 7 20 13 
8b 6.5 direct ascent 30      11 32.6  10† 22 17 
9a 6.5 direct ascent 15      9 32.1 1 12 7 
9b 6.5 A 14      9 33.8   2† 6 1 
9c 4.3 A 9      2 34.8 3 5 4 
9d 4.3 A 6      1 36.4 0 2 0 
9e 4.3 E,A 7      0 34.6 0 2 0 
10 10.1 FAD 14      5 31.7 1 6 3 
11a 4.3 P,A 16      12 33.2 3 9 4 
11b 6.5 direct ascent 1      3 39.5 0 1 0 
Phase I 4.3 P,E,S,A 33      14 29.1 9 23 2 
Phase II 4.3 P,E,S,A 35      10 31.7 0 14 3 
Phase III 4.3 P,E,S,A 8      1 29.9   2† 1 1 
Phase IV 4.3 P,E,S,A 44      12 30.1 8 23 7 
Phase V-1 4.3 P,E,A 7      2 31.5 3 5 2 
Phase V-2 4.3 P,E,A 1      2 39.2   1† 3 2 
Phase V-3 4.3 P,E,A 38      10 36.9 7 25 5 
Phase V-4 4.3 P,E,A 3      3 31.5 3 3 1 
Phase V-5 4.3 P,E,S,A 37      11 32.3 2 14 8 
 
*Conditions:  P, some PB occurred before ascent; S, a portion of the PB was spent at 10.2 psia breathing 26.5% O2; 
A, subjects were “adynamic” (no ambulation before or during the altitude exposure); E, a prescribed exercise was 
performed during some interval of the PB; FAD, flying after diving. 
† One case was classified as Type II DCS; †† Two cases were classified as Type II DCS. 
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As part of the NASA Prebreathe Reduction Program (PRP), several trials evaluated the benefits 
of different exercise regimens during PB: short and intense, long and mild, and combinations of 
the two.  The goal was to combine known factors that reduce the P(DCS), such as exercise and 
adynamia, with representative EVA work simulations using a PB protocol for ISS construction 
and maintenance.  Avoiding ambulation during PB and at altitude does reduce the incidence of 
DCS and VGE in the lower body, so adynamia is included in all current validation testing as an 
analog to working in µG (Powell et al. 1992, Conkin & Powell 2001, Vann & Gerth 1997), 
although there are contrary observations (Balldin et al. 2002).  In PRP Phases I through IV, 
researchers evaluated the influence of combined intense dual-cycle ergometry for 10 min with 
additional low-intensity exercise on the DCS and VGE outcome.  After completing the initial 50 
min of PB at site pressure, the subjects were depressurized to 10.2 psia over 30 min while still 
breathing 100% O2, and 30 min were then spent at 10.2 psia breathing 26.5% O2 to reproduce the 
suit donning conditions in the ISS airlock. Then, 100% O2 was reintroduced into their masks and 
they were repressurized to site pressure within 5 min to complete the final 35 min of PB.  After a 
150 min total PB time, a final depressurization from site pressure to 4.3 psia was completed in 30 
min, and the subjects simulated EVA work tasks at 4.3 psia for 4 hr.  Phase II met the accept 
conditions, as described earlier, for an ISS PB and became the operational Exercise PB protocol.  
In PRP trials from Phases V-1 to V-4, researchers evaluated whether mild exercise that could be 
performed during an in-suit PB at 14.7 psia would be effective, but none met the prospective 
acceptable conditions.  The final trials in this series (Phase V-5) extended mild exercise and the 
total PB time to 190 min, which included a 30-min suit donning step at 10.2 psia, and became the 
operational ISLE PB protocol.  Instead of referencing publications over a period of 30 years that 
cover the specifics of all trials, the reader can find details in Conkin et al. (2003, 2004) for trials 
from 1a to Phase IV.  Details from Phases V-1 to V-5 are provided in Gernhardt & Pollock 
(2006).   
 
1. Master Logic Diagram 
The goal of most ground-based research studies was to determine if a given operational PB 
protocol would reduce the P(DCS) to acceptable levels. Even under this operational research 
paradigm, where certain risk factors for DCS were not systematically evaluated, a growing body 
of evidence accumulated to describe certain factors that contribute to DCS. Known factors are 
shown in Figure 4, the Master Logic Diagram, which describes the various factors that contribute 
to DCS likelihood and consequence. Understanding of these factors is a result of variations of 
ground-based chamber studies of PB protocols intended to protect astronauts from DCS during 
EVA. 
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Figure 4. Understanding and managing DCS has many components, as seen in the Master Logic 
Diagram for DCS. 
	  
2. Inadequate Denitrogenation 
Much of the information about denitrogenation and hypobaric DCS that was learned during and 
shortly after World War II (WW II) is available on the pages of Fulton’s 1951 book (Bateman 
1951, Jones 1951), with additional information provided in the 4th edition of Fundamentals of 
Aerospace Medicine (Stepanek & Webb 2008) and The Proceedings of the 1990 Hypobaric 
Decompression Sickness Workshop (Pilmanis 1992).  The advent of Doppler ultrasound bubble 
detection technology in the 1970s provided a useful tool with which to understand DCS.  
Clearly, denitrogenation protocols are effective in reducing the P(DCS) and the severity of 
symptoms, as well as the potential for venous gas emboli (VGE) and arterial gas emboli (AGE).  
After denitrogenation, which typically involves oxygen (O2) prebreathing, an astronaut has a 
small amount of tissue nitrogen (N2) to manage. Once the astronaut depressurizes to a low-
pressure spacesuit, the volume expansion (Boyle’s Law) of this remaining N2 at the new lower 
pressure is concerning.  
One major contribution to how much N2 stays in the body after a PB is body fat content.  It is 
important to define the minimum PB time that protects the greatest number of EVA astronauts, 
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regardless of whether they are male or female and given a reasonable range of body types.  It is 
important to keep the PB procedure simple and to balance the risk of DCS with available 
treatment resources (McIver et al. 1967).  Risk is defined as the P(DCS) and the consequence of 
DCS, and because the consequence of a serious case of DCS in space is high, the P(Serious 
DCS) must be very low to achieve an acceptable operational risk. 
 
Males and females each display a wide range of body types.  A brief generic comparison using 
gender illustrates that no two people have the same quality or quantity of N2 elimination 
(washout) and uptake (washin).  Table 4 shows the estimated volume of N2 dissolved in lean and 
fat tissues in a representative male and female.  The total volume of N2 is slightly higher in 
women than men, given an N2 solubility coefficient of 0.0146 ml (STPD) N2/ml tissue * ATM N2 
in lean (aqueous) tissue and 0.0615 ml N2/ml tissue * ATM N2 in fat (lipid) tissue, as well as the 
other information in the table.  
 
Table 4. Estimated N2 content by gender. 
gender wt  
(kg) 
body fat % 
(% total wt) 
fat 
mass 
(kg) 
N2 volume 
in fat tissue 
(ml)* 
lean 
mass 
(kg) 
N2 volume 
in lean 
tissue (ml) 
total N2 
volume 
(ml) 
male 75 10 7.5 405 67.5 778 1183 
female 60 25 15.0 809 45.0 519 1328 
 * Density of fat = 0.9 g/ml, density of lean tissue = 1.1 g/ml, partial pressure of N2 = 0.79 ATA in 
breathing air, and total body weight was not reduced to compensate for the weight of inert bone.   
 
Apparent in this example is that the amount of N2 in fat tissues of women is twice that of men 
and that the amount of N2 in lean tissues of men is slightly greater than that in women.  Given 
enough PB time, the same total volume of N2 would be removed from men and women.  
However, PB time is always limited, so the kinetics of N2 elimination and the relative 
contributions of N2 from the fat and lean tissues during a limited PB must be considered. In this 
example, a large amount of N2 would quickly be eliminated from the well-perfused and large 
lean tissue reservoir in men, with a lesser amount of N2 coming from the poorly perfused fat 
depot that is smaller than that in women.  The poorly perfused fat contributes some N2 
throughout the PB but is likely responsible for the long tail of a typical N2 elimination curve.  
Females also provide a large amount of N2 initially removed from a well-perfused but smaller 
lean tissue reservoir, with a greater amount of N2 than that in men, which is derived from a 
poorly perfused fat depot that is larger than that in men.  The poorly perfused fat tissue has a 5-
fold greater affinity for N2 than does the well-perfused lean tissue.  As a result, a large amount of 
N2 is available from fat tissue in women and the N2 slowly leaves the body during PB, such that 
an even longer tail on a typical N2 elimination curve would be expected for women compared 
with men.   
 
It is important to define the minimum PB time that protects the greatest number of EVA 
astronauts, regardless of whether they are male or female and given a reasonable range of body 
types.  It is important to keep the PB procedure simple and to balance the risk of DCS with 
available treatment resources (McIver et al. 1967).  Risk is defined as the P(DCS) and the 
consequence of DCS, and because the consequence of a serious case of DCS in space is high, the 
P(serious DCS) must be very low to achieve an acceptable operational risk. 
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Air break during prebreathe: 
Various methods to preserve the quality of and confidence in the PB during the transition from 
the mask to the suit were evaluated at JSC, and all were found to be inadequate.  In effect, the 
inability to avoid a potentially long air break in PB at 14.7 psia and ignorance of the 
consequences of an air break during PB were responsible for the development of the staged 
denitrogenation protocols on the Shuttle and ISS (Horrigan & Waligora 1980, Powell et al. 
1994a).  The few research studies that exist about PB breaks are listed here in chronological 
order: Clarke et al. (1945), Bateman (1951), Cooke (1976), Adams et al. (1977), Horrigan et al. 
(1979), Dixon et al. (1980), Barer et al. (1983), and, most recently, Pilmanis et al. (2010). 
 
A lengthy break in PB is an operational reality that could compromise an otherwise safe 
denitrogenation procedure and jeopardize a scheduled EVA.  The NASA Aeromedical Flight 
Rules define O2 payback time based on the location and duration of a simple air break during a 
PB.  Payback time is the number of minutes of additional PB time needed to compensate for an 
interruption in the original PB time.  For air breaks during resting PB, the payback time on 100% 
O2 is 2 times the duration of the air break and 4 times the duration if the air break occurs early in 
the exercise PB protocol for the ISS.  A break in PB longer than 10 min requires that the PB be 
repeated from the start or that the crew switch to an alternative PB protocol.  A notable case of a 
complicated break in PB occurred during the preparations for the second of three EVAs on STS-
129.  A mechanical problem in the airlock control panel on the ISS occurred approximately 2 hr 
into the sleep period of the campout PB.  This failure initiated a repressurization of the airlock.  
There was no reasonable recovery from this air break due to the time needed to reconfigure the 
airlock operations.  The decision was made to switch to the exercise PB protocol, which was 
completed the following day and preserved the original scheduling of the second EVA.   
 
Estimates for PB payback time have ranged from 1 (Cooke 1976) to 35 times (Adams et al. 
1977) the duration of the air break.  Unfortunately, no published results exist that can be 
confidently applied to NASA operations.  There are simply no data on payback time if PB is 
interrupted during exercise.  Simple rules for PB compensation after an air break are desirable 
for space EVA operations, but no two people have identical N2 uptake and elimination kinetics, 
and in reality, the duration of the break, the point at which the interruption in the PB occurred, 
and the remaining amount of PB time are infinitely variable.  Breathing 1 ATA of O2 is known to 
decrease cardiac output and to increase peripheral vascular resistance by increasing 
vasoconstriction (Andersen & Hillestad 1970, Anderson et al. 1991).  It is reasonable to suppose 
asymmetrical N2 kinetics as a consequence of an air break.  It is also reasonable to suppose that 
there is a change in the size distribution of tissue micronuclei as a function of the O2 window 
during the PB (Van Liew et al. 1993), and the size distribution is influenced by air breaks.  Thus, 
simple payback rules may not suffice under all conditions, and a quantitative approach to 
assessing payback time is a goal for the future (Conkin 2011).   Data from Pilmanis et al. (2010) 
showed that a 10-min air break occurring 30 min into a 60-min PB prior to a 4.37-psia exposure 
did reduce the mean time to onset of symptoms and did increase the DCS incidence at 1 hr 
compared with controls. 
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Hypobaric ascent limit:   
The need for high-altitude bombing during WW II and the rapid advancement in jet engine 
development after the war put aviators at risk for DCS, hypoxia, and hypothermia until 
pressurized and air-conditioned aircraft cabins became common.  Before these technical 
advances occurred, researchers in Canada and the U.S. characterized DCS, mostly with young 
airmen in training, using hypobaric chambers (Fulton 1951, Adler 1964, Fryer & Roxburgh 
1965).  It was quickly realized that the altitude attained, the time spent at altitude, and exercise at 
altitude increased the risk of DCS, both pain-only DCS and serious DCS linked to reactions in 
the cardiovascular and nervous systems (Conkin 2001, Conkin et al. 2002).  Never again will 
such provocative testing be performed, and “modelers” of DCS must be content with these data 
to define the upper range of dose-response curves.   
Denitrogenation with enriched O2 mixtures dramatically reduced both pain-only and serious 
DCS, and most fit young men could tolerate a degree of depressurization even without the 
benefit of a PB.  During the war years, the criteria for a successful ascent centered around having 
enough time to perform the mission before DCS symptoms became debilitating.  Under these 
extreme conditions, ascents to between 6,096 and 7,620 m (20,000 and 25,000 ft) were 
acceptable in most operational settings.  Several studies were initiated to identify and then screen 
out personnel who were potential “weak links” as a means to reduce the impact of DCS on the 
mission.  These efforts were abandoned as ineffective and costly but highlighted the reality of 
between- and within-subject variability in DCS.  As the interest in aviator DCS increased after 
WW II, primarily through the United States Air Force (USAF) and NASA, a systematic 
approach led to a better understanding of hypobaric ascent limitations.  Additionally, a shift in 
thinking from “tolerable” symptoms to the first onset of mild symptoms reduced the threshold 
altitude for DCS. 
Each year, millions of people on commercial flights are quickly exposed to an altitude between 
1,829 and 2,438 m (6,000 and 8,000 ft) for long periods.  Most barophysiologists would agree 
that a rapid ascent to 3048 m (10,000 ft) is without significant risk of DCS, but hypoxia soon 
limits useful physical activity.  The use of enriched O2 at higher altitudes confounds the basic 
question about the DCS limit associated with direct ascent (Webb & Pilmanis 1993).  In addition 
to defining the threshold of evolved gas and the interaction of the evolved gas with living tissues 
that produce symptoms, there are practical reasons to define a hypobaric ascent limit.  
Prebreathing takes time and resources, and a spacesuit pressurized greater than the lowest 
pressure sufficient to cause venous gas emboli (VGE) and DCS could be an option to eliminate 
the risk of DCS (Flugel et al. 1984). 
Work to define the threshold for a no PB spacesuit suggests that a 4,420-m (14,500 ft) altitude is 
close to a no-DCS ascent, with VGE still produced at an altitude of 3,505 m (11,500 ft) (Conkin 
et al. 1990).  Webb et al. (1989) showed that a spacesuit at 9.5 psia (11,500 ft) prevented DCS 
during 5 repeated exposures in 22 subjects.  There is some threshold below which the gas that is 
evolved after depressurization is insufficient to elicit symptoms, even if it is difficult to establish 
this without exception. Table 5, modified from Conkin et al. (1990), lists hypobaric exposure 
pressures and the associated DCS and VGE incidence. 
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Table 5. Tests to find threshold altitudes for DCS and VGE. 
P1N2 / P2 P2 
(psia) 
DCS 
cases / n 
VGE 
cases / n 
reference 
1.49, day 1 of 3 7.8 2 / 64 = 3.0% 28 / 64 = 43% Dixon 1986,1988 
Conkin 1990 
1.43, day 2 of 3 7.8 2 / 62 = 3.0% 29 / 62 = 46% Dixon 1986,1988 
Conkin 1990 
1.42, day 3 of 3 7.8 1 / 60 = 1.6% 25 / 60 = 41% Dixon 1986,1988 
Conkin 1990 
1.40 8.3 1 / 31 = 3.2% 8 / 31 = 26% Webb 1988, Smead 
1986, 
1.36 8.5 0 / 9 = 0% 3 / 9 = 33% USAF pilot study* 
Conkin 1990 
1.29 9.0 0 / 16 = 0% 7 / 16 = 43% USAF pilot study* 
Conkin 1990 
1.22 9.5 0 / 6 = 0% 1 / 6 = 17% USAF pilot study* 
Conkin 1990 
1.22 9.5 0 / 31 = 0% 8 / 31 = 26% USAF pilot study* 
Conkin 1990 
1.22, day 1 of 5 9.5 0 / 23 = 0%  0 / 23 = 0% Webb 1989, Dixon 
1985, Conkin 1990 
1.11, day 2 of 5 9.5 0 / 22 = 0%  0 / 22 = 0% Webb 1989, Dixon 
1985, Conkin 1990 
1.10, day 3 of 5 9.5 0 / 22 = 0%  0 / 22 = 0% Webb 1989, Dixon 
1985, Conkin 1990 
1.10, day 4 of 5 9.5 0 / 22 = 0%  0 / 22 = 0% Webb 1989, Dixon 
1985, Conkin 1990 
1.10, day 5 of 5 9.5 0 / 22 = 0%  0 / 22 = 0% Webb 1989, Dixon 
1985, Conkin 1990 
1.16 10.0 0 / 8 = 0% 2 / 8 = 25% USAF pilot study* 
Conkin 1990 
*USAF pilot studies using subjects with a history of DCS and VGE. 
 
Kumar et al. (1990) and Webb et al. (1998) summarized the information in Table 1 and other 
information about altitude threshold, but they came to different conclusions.  Kumar stressed that 
any threshold for symptoms is conditional on other factors, with his lowest conditional threshold 
defined as a 3,353-m (11,000 ft) altitude.  Webb reported a DCS incidence of approximately 5% 
for an altitude of 6,096 m (20,000 ft).  Probing for the lowest decompression dose to elicit 
symptoms is a difficult task, as there are always exceptions to the rule (Rudge 1990b, Voge 
1989).  
 
3. Activity During EVA 
No single variable, other than O2 PB time, has more of an impact on the P(DCS) than exercise at 
altitude.  Cook (1951) summarized the importance of exercise at altitude as a factor associated 
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with an increase in the incidence and severity of DCS, as well as a shortened latency time to the 
first report of DCS.  One can limit the P(DCS) at a given suit pressure by limiting exercise 
during EVA, but this is impractical in most scenarios because astronauts are performing physical 
tasks during an EVA.  The general approach is to provide sufficient PB so that the type, 
intensity, and duration of EVA work are not considerations.  Ambulation that stresses the knees 
and ankles on the surface of the moon or Mars is expected to increase the risk of DCS for any PB 
protocol that otherwise performed well in µG (Conkin et al. 1987, Conkin et al. 2001, Webb et 
al. 2010). 
 
Figure 5 is a classic presentation of the importance of exercise type and intensity toward the 
P(DCS).  The figure is redrawn from Henry (1956).  It shows the rate of DCS as a function of 
lower-body exercise intensity during a stair-step challenge.    
 
 
Figure 5. The rate of DCS as a result of exercise after an ascent to 3.0 psia without PB.  
Standard exercise was 10 step-ups on a 9-in stool in 30 sec, repeated at 5-min intervals.   
 
4. Exercise Effects on Micronuclei 
The previous discussion focused on reducing the amount of tissue N2 to limit bubble growth, the 
classic Haldanean approach, but an emerging area of DCS prevention is to also hinder the 
transformation of tissue micronuclei into growing bubbles (Tikuisis & Gerth 2003, Blatteau et al. 
2006).  The presence of gaseous micronuclei in the tissues permits DCS under modest 
depressurizations (Weathersby et al. 1982).  Information about and evidence for tissue 
micronuclei are primarily derived from indirect observations. One consistent inference from 
these studies is that normal activity establishes a size distribution of micronuclei within tissues, 
which can then be modified by changing the type, timing, and intensity of activity.  
  
If micronuclei are considered and if the results from research on DCS are then applied to 
astronauts who perform EVAs, then walking in an altitude chamber is not a reasonable analog to 
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EVA or “space walking” (Powell et al. 1992, Powell et al. 1993, Vann & Gerth 1997).  Exercise 
during depressurization increases the risk of DCS, generally in the limb performing the exercise 
(Conkin et al. 1987, Cooke 1951, Henry 1956, Krutz & Dixon 1987).  Walking is such a natural 
event that, in research on DCS, it is frequently ignored as being exercise.  This simple and 
ubiquitous act has new relevance as humans venture into space and when they ambulate on the 
moon and later Mars, especially as it relates to the risk of DCS.  Calling an EVA in µG from the 
Shuttle or ISS a ‘spacewalk’ is a misnomer.  Astronauts do not ambulate in the conventional 
sense but only anchor their legs to a stable structure so that the upper body can perform some 
task.  Powell coined the term “adynamia” to characterize the lack of movement and, therefore, 
the lack of dynamic forces in the lower body (lower body adynamia) over several days of 
adaptation to µG and during EVAs (Powell et al. 1994, 1995, Kumar et al. 1993a, Conkin & 
Powell 2001).   
 
The fundamental premise of adynamia is the control of nucleation processes within tissues and 
fluids.  In the absence of supersaturation, the spontaneous rate of nucleation is inconsequential 
when micronuclei on the order of microns in radius are considered.  However, the number or 
distribution of micronucleus sizes can be influenced before supersaturation exists when 
mechanical energy is added to the system.  It is notable that subjects who performed brief but 
vigorous dual-cycle (arms and legs) ergometry at the start of an exercise PB showed earlier VGE 
onset compared with those who performed the ergometry approximately 15 min into the start of 
the PB (Conkin et al. 2004).  A 15-min delay in starting the ergometry in a 150-min total PB 
time delayed the VGE onset time in research subjects during a subsequent exposure to 4.3 psia.  
Astronauts always perform EVAs in pairs.  Thus, astronauts who use the Exercise PB protocol 
start the PB at the same time, but someone must go first because there is only one leg ergometer 
on the ISS dedicated to this protocol.   
 
Violent muscular contractions in bullfrogs before a hypobaric exposure (Whitaker et al. 1945) 
were associated with bubble formation in the resting animals while at altitude.  The number of 
bubbles was reduced if the frogs were allowed to recover for as long as 1 hr after electrical 
stimulations.  The authors offered 2 explanations for this finding:  a short-lived local increase in 
carbon dioxide (CO2) that facilitated bubble growth at altitude, or the inception of micronuclei or 
some other short-lived entities that would later facilitate the growth of bubbles at altitude.  This 
same concept was tested in humans (Dervay et al. 2002) when 20 subjects were exposed to 6.2 
psia on 3 separate and random occasions without the confounding of PB or any exercise at 
altitude during a 2-hr exposure.  Each subject performed 150 deep knee flexes in 10 min either 2 
hr, 1 hr, or just before ascent, with the remaining time spent adynamic in a chair.  It was 
hypothesized that exercise before decompression would generate a population of some entity 
(micronuclei, macronuclei, vapor-filled cavities trapped on vascular endothelium, or an increase 
in the concentration of CO2) that would diminish in size or concentration given enough time 
before ascent.  The investigators used subsequent VGE information to indirectly test this 
hypothesis.  They observed that intense lower-body activity just before the altitude exposure did 
cause more VGE to appear and caused them to appear earlier than when exercise was performed 
earlier.  The critical observation was that the predisposing factor(s) diminished with time while 
subjects sat quietly in a chair before the ascent. 
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If DCS outcome is related only to tissue N2 supersaturation, then perhaps the decrease in P(DCS) 
tracks the decrease in computed supersaturation.  If the relationship is not a mirror image, then 
perhaps factors other than N2 supersaturation are co-responsible.  The dashed line in Fig. 3 is 
from the natural logarithm transformation of the exponential decay in a 360-min half-time 
compartment normalized by dividing the initial tissue N2 pressure by 11.6 psia, the ambient pN2 
at sea level.  The solid curve is the same transformation applied to the P(DCS) from a survival 
model (Conkin et al. 1996) evaluated over 6 hr of PB given that the person performed mild 
exercise at 4.3 psia for 4 hr while breathing 100% O2 through a mask.  Other factors that dictate 
the DCS outcome must exist besides tissue N2 supersaturation or the 2 plots would look similar.  
If DCS outcome is a complex competition between the potential for evolved gas and the 
transformation of micronuclei into bubbles, it might be expected that the curves for log[P(DCS)] 
and log(normalized N2 pressure) would diverge over a range of PB times.   
 
The physics of micronucleus stability, creation, size distribution, absolute numbers in tissues, 
and transformation into growing bubbles for a given N2 supersaturation must be complex (Van 
Liew & Raychaudhuri 1997, Van Liew 1998, Van Liew & Conkin 2007).  One could 
hypothesize that only a few large-radius micronuclei could be absorbed during a short 100% O2 
PB and that more large- and small-radius micronuclei are absorbed after more than 90 min of 
PB.  There would come a point during a long PB where fewer and smaller-radius micronuclei 
exist to subsequently transform into growing bubbles under the prevailing reduced N2 
supersaturation, as suggested by the rapid decrease in ln[P(DCS)] after 3 hr of PB in the survival 
model (Figure 6).  The reality of bubble growth in tissue is that it is not just the absolute potential 
for evolved gas, as reflected in an exponential washout curve, but it is a competition between the 
potential for available gas and the population of micronuclei that are available to accept the 
excess gas and transform into growing bubbles.  The acceptance of this excess gas occurs 
through simple diffusion, but that is the only simple statement possible.     
 
Figure 6. Change in computed tissue N2 pressure (dashed curve) and the P(DCS) (solid curve) as 
a function of PB time under conditions of the simulation described in the text.   
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The classic soda-bottle analogy of bubbles in the body illustrates the physical consequence of 
depressurization, but emerging science suggests that activation of various stress-induced 
biomolecules before, during, or after depressurization will influence the DCS and VGE outcomes 
(Dujić et al. 2006, Valic et al. 2007).  Astronauts routinely take aspirin and other 
pharmacological agents to manage the stress and discomforts of space flight and EVAs, which 
may influence the DCS and VGE outcomes.  The large surface area of the vascular endothelium 
and its interaction with stress-induced biomolecules offers an opportunity to understand how 
excess intracellular dissolved gas actually becomes extracellular evolved gas bubbles that are 
then relocated to the lungs (Wisloff et al. 2004). 
 
5. Duration of EVA 
The evolution of gas in tissue is a time-dependent process.  Nims (1951) systematically describes 
the time-dependent process in the development of his theoretical model to describe aviator DCS.  
Gas evolution has a lag phase, a growth phase, and finally a recovery phase if the EVA continues 
since tissue and bubble N2 continues to be removed while breathing 100% O2 during the EVA.  
One can limit the P(DCS) at a given suit pressure by limiting the EVA exposure time, but this is 
impractical in most applications.  The general approach is to provide sufficient PB so that EVA 
duration is not a consideration.  
 
Figure 7 shows the distribution of symptom failure times from denitrogenation protocols that are 
considered conservative, based on NASA PB validations.  Symptom failure times were generally 
75 to 175 min in these studies, with fewer cases appearing in minutes and others at 6 hrs.  There 
is a period during any EVA, approximately 3 hrs, after which the likelihood is small that DCS 
will be reported.  Again, this is attributed to the continued removal of N2 during the course of an 
EVA.  
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Figure 7. Histogram time distribution of 216 symptoms in 119 cases of DCS.  The distribution is 
skewed right, with the largest number of DCS reports occurring approximately 120 min into the 
exposures. 
 
6. Physiological Predisposition and Risk of DCS 
It has been observed that some divers and aviators are particularly resistant or susceptible to 
DCS and VGE (Weathersby 1989, Kumar et al. 1992, Webb et al. 2005).  Depressurization 
schedules developed to protect the most susceptible individuals are then ultra-safe for the 
resistant individuals and are therefore not very efficient.  Thus, there is a long history of 
persistent efforts to identify those who are susceptible and to identify the physiological and 
anatomical factors associated, as either a cause or a correlate, with susceptibility (Allen et al. 
1971).  Selection schemes, except for natural selection, have not developed past the conceptual 
stage primarily because prospective, well-controlled studies with adequate sample sizes are 
expensive.  
 
Table 6 lists examples of factors associated with the risk of DCS and the associated references. 
Any global conclusions on individual factors are confounded by inconsistencies in the DCS 
mitigation strategy (primarily PB duration) and decompression dose and duration. Law and 
Watkins (2010) reviewed literature on individual susceptibility to DCS but provided no 
additional recommendations for astronaut screening and did not refute the current practice of 
eliminating astronaut candidates due to flow-significant atrial septal defects. 
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Table 6. Individual Factors Associated with Risk of DCS and VGE. 
Factors Associated with 
Risk of DCS and VGE 
Some Reference(s) 
Age Conkin et al. 2003, Eckenhoff et al. 1990, Cameron et al. 
2007, Sulaiman et al. 1997, Carturan et al. 2002, Schellart 
et al. 2012 
PFO Saary & Gray 2001, Foster et al. 2003 
Gender Webb et al. 2003, Conkin 2010, Thompson et al. 2003, 
Vann et al. 1993 
Menstrual Cycle Time Rudge 1990a, Webb et al. 2003  
Aerobic Fitness Dujić et al. 2004, 2008, Carturan et al. 1999, Webb et al. 
2003, Webb et al. 2005 
Body Fat  Webb et al. 2003, Webb et al. 2005 
Hydration Status Fahlman & Dromsky 2006 
 
One challenge in understanding the contribution of these factors to DCS and VGE outcomes is 
that all are part of the whole, and it is difficult to isolate the contribution of one factor.  In reality, 
DCS and VGE outcomes are multifactorial and confounded by many factors, particularly the 
decompression dose (Kumar et al. 1993). 
 
A practical approach, given a large sample of quality research results, is to perform a 
multivariate statistical analysis in which the uniqueness of each trial becomes part of the reason, 
along with other explanatory variables, for the outcome.  In other words, a multivariate analysis, 
such as logistic regression or survival analysis, identifies and controls for confounding and 
interacting variables so that a better interpretation of the outcome is possible (Conkin 1994, 
Kumar & Powell 1994).  Although a multivariate analysis with large numbers of quality research 
data with an appropriate range of explanatory variables is necessary to assign the appropriate 
contribution to an explanatory variable, in general, this approach has not been used and 
contributes to contradiction and confusion in the literature. 
 
With limited objective data to support specific recommendations for astronaut selection and 
preparation, we are left with suggesting that an astronaut should be adequately hydrated prior to 
EVA and that increased aerobic fitness and lower body fat levels may contribute slightly to 
decreased DCS risk.  
 
7. Relationship Between VGE and Hypobaric DCS 
Since silent bubbles were associated with modest hyperbaric and hypobaric exposures, there has 
been a vigorous debate about the value of VGE detected in the pulmonary artery or other veins in 
predicting subsequent DCS outcomes (Nishi 1993).  The fact that bubbles are present without 
overt symptoms suggests that, at best, the presence of VGE is a necessary but not sufficient 
condition for DCS, and relationships between the two are correlative as opposed to cause-and-
effect.  Correlative relationships differ from one study to the next depending on many factors, 
such as the decompression dose and the type of breathing gas (Webb & Pilmanis 1993, Pilmanis 
et al. 2003), the type of ultrasound equipment, training of the Doppler technician, and the 
methods used to quantify the Doppler signals (e.g., simple bubble grades or more sophisticated 
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“time-intensity” approaches) (Eftedal et al. 2007).  However, the absence of VGE is strongly 
associated with the absence of DCS.   
 
The positive and negative predictive values of VGE have been explored in both divers and 
aviators (Nishi 1993, Kumar et al. 1992a, Kumar & Waligora 1995, Conkin et al. 1998).  The 
desire to have a single global understanding of the relationship between VGE and DCS is 
frustrated because of differences in bubbles between divers and aviators, and even differences 
attributed to gender (Conkin 2010).  Trials that produce Grade IV VGE in 50% of divers will 
never be sanctioned because this would result in an unacceptably high incidence of DCS, as well 
as a high incidence of serious DCS.  However, Grade IV VGE-producing trials are routinely 
assigned in hypobaric depressurizations, even after conservative PBs (Webb et al. 2002).  DCS 
incidence on the order of 20% is common, with only approximately 1% of all exposures resulting 
in serious DCS in NASA testing and a higher percentage in tests of protocols for the USAF 
(Balldin et al. 2004).  Divers returning to 1 ATA from a provocative SCUBA dive may produce 
many small bubbles, predominately composed of N2.  In contrast, aviators may produce fewer 
large bubbles composed of as much as 70% metabolic gases (Van Liew & Burkard 1994, 1995, 
Van Liew et al. 1993).  Because the gas composition of VGE in divers and aviators is different, 
it is reasonable to expect that the association between VGE and DCS reflects this difference.  In 
summary, a global understanding about the relationship between VGE and DCS is not yet 
available.  The absence of this understanding results in contradictions when the experiences of 
divers and aviators are compared. 
 
It is more than coincidental that VGEs are often detected in high intensity coming from a region 
of the body where a sign or symptom may appear. Table 7 shows that the positive predictive 
value for DCS of any VGE grade or of Grade III and IV is only 32 or 39% (Conkin et al. 1996a).  
Someone with prior knowledge of even Grade IV VGE from a particular limb in an aviator is 
less than 40% confident that a DCS symptom will follow.  The absence of VGE has a negative 
predictive value of 98% based on these data, with a much lower value based on other hypobaric 
data (Olson et al. 1988, Balldin et al. 2002).  Thus, it is more informative to know that an aviator 
or astronaut has no VGE in the pulmonary artery if the goal is to predict a subsequent DCS 
outcome (Kumar et al. 1997). 
 
Table 7. Measures of association between VGE and DCS 
measure Grades 0 – IV (n  = 1,322) Grades 0, III, IV (n = 1,210) 
sensitivity 0.922 0.917 
specificity 0.718 0.787 
+ predictive value 0.323 0.391 
- predictive value 0.980 0.980 
 
Even though a one-to-one cause-and-effect relationship between VGE and DCS does not exist, 
there is a consistent temporal association between VGE and DCS.  Figure 8 shows this temporal 
pattern.  Not everyone who has VGE has subsequent DCS, and a few people who do not have 
VGE do have DCS.  The caveat here is that a similar VGE onset and recovery pattern is present 
in those who do and those who do not develop DCS.  Any association between VGE detected in 
the pulmonary artery and pain-only DCS in a distant limb is subtle.   
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Figure 8. Time of VGE and DCS onset in 78 exposures in which both VGE and DCS were 
present (solid curve) and in 150 exposures in which only VGE was present (dashed curve).  The 
curves, all of which are skewed to the right, are the best-imposed normal distributions on 
histograms. 
 
The NASA Hypobaric Decompression Sickness Database contains data on 78 subjects with DCS 
onset times associated with 78 VGE onset times, with a mean TR of 1.67 ± 0.15.  The mean DCS 
onset time was 120 ± 71 min, and the mean VGE onset time was 72 ± 55 min.  In 150 other 
exposures, VGEs were not associated with a report of DCS.  The 150 exposures associated with 
VGE but not DCS had a mean VGE onset time of 90 ± 65 min and a mean TR of 1.65 ± 0.19.  
The mean VGE onset time for all 228 exposures associated with VGEs was 84 ± 62 min.  Only 4 
subjects had DCS without VGE being detected.  The majority of exposure individuals, a total of 
317 of 549 (57.7%), had no DCS or VGE, as the goal was to validate only safe PB protocols.  
The same pattern held for exercise during PB, but the incidence of DCS given that VGEs were 
present decreased slightly from 14% to 11%.  It was likely, but not certain, that an individual 
would report a DCS symptom after VGEs were detected if they were detected early in the 
altitude exposure, if the intensity or grade of VGE from a limb region increased rapidly, and if 
the intensity or grade of VGE remained high (Conkin et al. 1996a, 1998). 
    
It is appropriate here to speculate on why VGEs detected in the pulmonary artery seem 
disconnected from the DCS outcome even when the VGEs seem to originate from a limb region.  
VGEs moving in the venous blood and detected at a common location throughout the cardiac 
cycle are far removed from the site of bubble formation, so there is no guarantee that other 
tissues, such as fat and skin, do not contribute VGEs to the venous return.  There is no a priori 
reason why VGE cannot be produced in a limb region even if the critical volume of evolved gas 
needed to evoke a symptom has not been reached.  Excess dissolved N2 in muscles, tendons, 
ligaments, joints, cartilage, and other tissues can form bubbles in these tissues and can also 
diffuse into the low-pressure venous return where bubbles grow from micronuclei clinging to the 
vascular endothelium.  They accumulate, grow, and then pinch off and coalesce, to be carried 
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with the venous return as muscle contractions “milk” the blood and bubbles into the venous 
return.  Thus, it is understandable that VGEs detected in the pulmonary artery are only indirectly 
linked to DCS symptoms.  However, even a weak association is helpful for visualizing the 
primary cause of a symptom at a distant location and the transport of excess N2 as bubbles.  
Advances in ultrasound technology will soon replace speculation, with clear visual evidence of 
stationary bubbles growing within tissues and on the vascular endothelium.   
 
It is preferable from a DCS standpoint to not have circulating VGEs, with or without a PFO.  
Blood is a complex fluid, and the blood-endothelial interface forms a complex homeostatic 
surface; thus, the presence of bubbles in blood and at the blood-endothelial interface could be 
problematic.  Aviators and astronauts share one feature with divers, namely healthy lungs that 
provide an efficient filter for VGEs (Diesel et al. 2002).  However, aviators and astronauts are 
not immune to the consequences of embolic overload, even if they have healthy lungs.  Many 
factors in the aerospace environment compromise healthy lung function.  These factors 
combined with too many bubbles entering the pulmonary circulation can put this group at high 
risk (Balldin et al. 2002). 
 
In-suit Doppler Effort: 
Monitoring for VGE in the pulmonary artery as the entire right-heart cardiac output enters the 
pulmonary circulation is the simplest approach for obtaining an unbiased assessment of the 
effective decompression dose, even if VGE are not directly linked to subsequent DCS.  
Noninvasive Doppler ultrasound bubble detection technology quickly advanced in the mid-1970s 
to the point where small, battery-operated devices were safe to use in operational settings.  
Investigators at Brooks AFB in the early 1980s proposed that a 5-mHz continuous-wave bubble 
detector with simple analog recording be interfaced with the U-2 aircraft pressure garment.  
However, scientific rationale and engineering capability were not enough to implement this 
system, even as a research tool.  The idea was valid and the rewards were great, so efforts 
persisted at JSC to provide an automated venous blood bubble monitor for use in the EMU.  
Several prototypes were developed and tested at JSC.  A parallel effort was also initiated by the 
Russians, who eventually monitored subjects in the Orlan suit during altitude chamber flights.   
 
The ability to acquire a stable, quality blood flow signal was verified during brief periods of µG 
during parabolic flight.  The viscera within the chest stabilized in µG, which allowed for good 
signal quality even under modest body motion (Hadley et al. 1984).  Technical advances 
continued, especially in the design of the probe.  The final configuration was a triangular flat 
probe head with 1 transmitting and 3 receiving sensors spaced so that a rib was always spanned 
regardless of the probe orientation on the chest over the pulmonary artery.  The sensor had to 
perform in a "hands off" operation once the EMU was donned.  Various taping and strapping 
options were evaluated to maintain orientation of the probe.  Techniques to maintain the 
ultrasound coupling between the sensor and skin were needed because one hour of use in a 
hypobaric environment would evaporate the ultrasound gel.  Issues of suit fit with the Doppler 
device inside the EMU were evaluated during normal training activities at the NBL.  A final 
design emerged where the battery module, 2.4-mHz continuous-wave ultrasound electronic 
module, and digital recorder module were separate on a belt worn around the waist.  The system 
was flown on STS-87 and worn by Winston Scott while in the Shuttle, not in the EMU.  The 
system was evaluated at 6.5 psia in 4 subjects in an altitude chamber (Test 11b) and recorded 
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VGE in 1 subject.  Finally, the system was used in the underwater habitat Aquarius where 
astronauts on the NEEMO 5 mission wore the unit for several hours after returning from dives 
deeper than the 56 FSW saturation depth of the habitat.  A significant finding was the recording 
of false-positive VGE signals.  Gas entrained by swallowing liquids was detected due to the 
proximity of the sensor to the esophagus (Acock et al. 2004, Gernhardt et al. 2005).  This was 
significant because astronauts are encouraged to drink water from a 32-ounce drink bag within 
the EMU during long EVAs.  The Doppler device, training, and use of the device under real-
world conditions were successful. 
 
Despite a successful research and development program for an automated in-suit bubble detector, 
a final operational system did not materialize.  Safety concerns about the battery-operated device 
within the 100% O2 EMU environment halted the effort and also prevented exposure of an 
astronaut to 4.3 psia while shirtsleeve in the Shuttle or ISS airlock as a means to evaluate the 
device.  There was also an understandable resistance to implement this system due to concerns 
that the results could impact future EVA assignments.   
  
Risk of Decompression Sickness (DCS) 
 
 
44 
V. DCS Treatment Experience 
The many signs and symptoms as a consequence of evolved gas and a review of treatment 
options for those afflicted are briefly described using data from NASA.  The reader is also 
referred to Norfleet (2008), Stepanek & Webb (2008a), Balldin et al. (2004), Ryles & Pilmanis 
(1996), Krause & Pilmanis (2000), Muehlberger et al. (2004), Conkin et al. (2003), and Jersey et 
al. (2010) for descriptions of what aviators and astronauts need to avoid to stay healthy and 
productive, as well as treatment options if evolved gas is not prevented. 
 
A PB protocol selected for EVAs in future Exploration-class missions will be conservative.  
However, even conservative PB protocols come with some risk.  What should mission managers 
expect as far as the prevalence and characteristics of symptoms?  How effective is a return to 
habitat pressure after the EVA to resolve symptoms?  What percentage of symptoms that resolve 
before a return to site pressure reoccur and require initiation of a hyperbaric O2 (HBO) 
treatment?  These and other questions are addressed by discussing the 220 symptoms associated 
with the 119 cases of DCS that have accrued during hypobaric chamber studies conducted by 
NASA. Conkin et al. (2003) discussed 103 of these cases in detail from 1982-1999. These and 
more recent DCS cases are being analyzed with the intent to develop a DCS treatment model 
(Conkin et al. 2013).  Additionally, the effectiveness of treating symptoms at the conclusion of 
an EVA is described using a bubble model.  
 
Figure 9 shows the number of Type I symptoms associated with an approximate anatomical 
location.  The knees and ankles contribute 139 occurrences (68%) out of 203 Type I symptom 
occurrences.  These data reflect results where subjects were ambulatory before and during the 
altitude exposure, but even subjects that were not ambulatory (adynamic) before and during the 
exposure had pain-only symptoms predominantly in the lower body.  Clearly, the lower body 
(feet, ankles, knees) is a primary location for DCS symptoms and is not expected to change in 
astronauts who ambulate on the surface of Mars or the moon. 
 
Figure 10 shows the number of Type I symptom attributes.  Pain as a symptom attribute that was 
constant in nature dominates how Type I symptoms were described by subjects.   
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Figure 9. Number of Type I symptom occurrences in 119 cases of DCS.  Symptoms in toes or 
fingers were included in the "feet" or "hands" categories.  One subject had skin symptoms 
(tingling) located in 7 body locations. 
 
Figure 10. Number of Type I symptom attributes in 119 cases of DCS.  Seven of the 9 cases of 
“tingling” symptoms came from 1 subject.  The two symptoms of numbness were attributed to 
impaired circulation and were not neurological in origin. 
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Figure 11 shows the number of Type II symptom attributes from 7 cases classified as Type II 
DCS.  The low number of  Type II symptoms limit any meaningful conclusions.  
 
 
Figure 11. One of 3 headaches in this figure was classified as Type I DCS.  Headache and a 
sensation of being hot during an otherwise unremarkable 4-hr test caused the symptom of 
“headache” to be classified as Type I DCS in a female.  However, the subject later reported 
having Type I symptoms and underwent HBO treatment.  Chest mottling (cutis marmorata) was 
initially classified as Type II DCS at JSC but now exists as its own category of DCS – not Type I 
or Type II.  It is shown on this graph in its historical context. 
 
Once a symptom appears during a validation test, it must be completely resolved before the 
subject is released by the Medical Officer. Figure 12 shows the cumulative percentage of 
symptoms that resolved at the given pressure difference.  Thirty-seven symptoms (19%) resolved 
at the test altitude, before repressurization; 122 symptoms (63%) resolved during 
repressurization; 14 symptoms (7.2%) resolved at site pressure (14.5 to 14.7 psia); and 21 
symptoms (10.8%) were persistent at site pressure and resolved during HBO treatment (USN 
Treatment Table V or VI).  Not represented in the figure are 11 symptoms that initially resolved 
prior to the subject being released from the test but reoccurred later and required initiation of 
HBO treatment.  Given the lengthy denitrogenation provided to NASA subjects, 89% of 194 
symptoms resolved over a pressure difference of 10.4 psia with 50% resolution over a pressure 
difference of just 3 psia.  
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Figure 12. The cumulative percentage of 194 symptoms that resolved at the given pressure 
difference defined as the pressure associated with symptom resolution minus the altitude test 
pressure, in units of psia.   
 
Figure 13 shows NASA data on the cumulative percentage of 194 symptoms that resolved at a 
given pressure difference up to total recompression.  A comparison of this NASA data to a much 
larger dataset of 1,699 resolved DCS symptoms from Muehlberger et al. (2004) reveals 
similarities despite the presence of approximately nine times more data from Brooks AFB.  For 
example, 19.0% of symptoms resolved at the test altitude based on the NASA data compared 
with 4.4% based on the USAF data, and 81.9% of all symptoms based on the NASA data 
resolved before reaching site pressure compared with 88.2% based on the USAF data.  Fifty 
percent of symptoms resolved based on the NASA data after the application of 160 mmHg of 
pressure compared with 138 mmHg for the USAF data.  Seventy-five percent of symptoms 
resolved based on the NASA data after applying 340 mmHg of pressure, compared with 250 
mmHg for the USAF data. 
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Figure 13. The majority of data is the same as presented in Figure 12 with an expanded x-axis 
and pressure difference converted to mmHg. 
Figure 14 shows 3 examples to demonstrate the resolution of a Bubble Growth Index (BGI) of 14 
units given a Boyle’s Law decrease in bubble volume with applied treatment pressure and the 
bubble-to-tissue N2 gradient as computed with the BGI model (Gernhardt 1991).  The BGI is the 
ratio of the final bubble radius to an initial bubble radius of 3 microns.   
 
The first curve from the left is derived from data obtained after a 60-min PB in an astronaut 
exposed to 4.3 psia with return to 14.7 psia, the second curve presents data from a saturation 
diver with return to 41.1 psia after exposure to14.7 psia, and the third curve is derived from data 
obtained after a 300-min PB in an astronaut exposed to 4.3 psia with return to 14.7 psia (5 min 
for all pressure transitions).  The elapsed time from the start of decreased pressure (time 0) to 
bubble resolution is shorter in the astronaut cases, dependent on the PB time, compared with the 
saturation diver.  The difference is due to a slight Boyle’s Law advantage during the return to site 
pressure (14.7 psia for the astronauts and 41.1 psia for the saturation diver) combined with a 
greater bubble-to-tissue N2 gradient for the astronaut with the longer PB compared with the 
saturation diver.   
 
A tentative conclusion based on only 3 examples and multiple assumptions in the BGI model is 
that the time is shorter to resolve a theoretical bubble for an astronaut treated with 100% O2 at 1 
ATA compared with a saturation diver treated with 100% O2 at 2.8 ATA (his saturation pressure 
and the treatment pressure for the USN TT V).  One other complication for the diver is the high 
pO2 during treatment, a level that must be reduced during “air breaks” to prevent CNS or 
pulmonary O2 toxicity.  This complexity was not included in the simulation and is not a 
complexity that the astronaut must face because 100% O2 at 1 ATA is well-tolerated for several 
hours.  
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Figure 14. The resolution of a 14-unit BGI given a Boyle’s Law decrease in bubble volume with 
applied treatment pressure and the bubble-to-tissue N2 gradient. The first curve from the left is 
derived from data obtained after a 60-min PB in an astronaut exposed to 4.3 psia with return to 
14.7 psia; the second curve represents data from a saturation diver with return to 41.1 psia after 
exposure to 14.7 psia; and the third curve is derived from data obtained after a 300-min PB in an 
astronaut exposed to 4.3 psia with return to 14.7 psia (5 min for all pressure transitions).   
 
DCS treatment on ISS follows a flow diagram designed to treat symptoms and evolved gas by 
keeping the astronaut in the suit breathing 100% O2 at 4.3 psid (19.0 psia) for prescribed 
intervals of time.  A limited neurological examination is available that assesses the suited 
astronaut during the course of treatment.  The return from 4.3 psia to even 14.7 psia on ISS 
causes a 71% Boyle’s Law decrease in a unit volume of gas, compared with a 64% decrease in a 
unit volume of gas in a diver that is treated at 2.8 ATA (41.1 psia).  Remaining in the suit and 
pressurized to 19.0 psia causes a 77% decrease in a unit volume of gas.  In the event symptoms 
do not resolve at 19.0 psia, the Bends Treatment Adapter (BTA) is installed without 
depressurizing the suit.  The suit is further pressurized to 8.0 psid (22.7 psia), resulting in an 81% 
decrease in a unit volume of gas, significantly better than the case in a diver seeking treatment on 
a USN TT V. Although an effective treatment option, the use of the BTA results in an EMU that 
is no longer certified for EVA.  A return to site pressure (see Fig. 11) is expected to resolve most 
symptoms, and the option to treat a persistent, recurrent, or Type II symptom at 22.7 psia with 
100% O2 using the BTA is expected to be effective.  The option to return an astronaut to Earth 
for additional treatment was possible with the shuttle from the ISS but is not an option with the 
Russian Soyuz and will not be an option for missions to the moon, Mars, or deep space.   
 
Providing DCS treatment options and any adjunctive therapy for Exploration-class missions 
should follow an evidence-based approach.  The approach needs to ultimately match the most 
effective treatment for the anticipated risks, as providing proper medical treatment at remote 
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locations is both costly and impacts the success of the mission (John-Baptiste et al. 2006, Rudge 
1992, Krause & Pilmanis 2000, Dowell 1993, and Butler et al. 2002). 
VI. Risk in Context of Exploration Mission Operational Scenarios    
As of August 2013, there have been no reported cases of DCS during Shuttle and ISS missions 
due to adherence to rigorously developed PB protocols that were specifically validated for 
Shuttle and ISS operational environments and EVA scenarios. Although DCS risk has been 
greatly reduced through these PB protocols, it is at the expense of significant crew time and 
consumable usage. This need for significant crew time and consumables will not meet the needs 
of the Exploration program. 
 
The architectures being developed by NASA for future exploration beyond low-Earth orbit differ 
from previous vehicles and EVA systems in terms of vehicle saturation pressures, breathing 
mixtures, EVA frequency, EVA durations, and pressure profiles, and they will almost certainly 
differ in terms of the definition of acceptable DCS risk and in-situ DCS treatment capabilities. 
The use of suit ports, variable-pressure EVA suits, intermittent recompressions, and possibly 
abbreviated purges with PB gas mixtures of less than 100% oxygen represents a paradigm shift 
in the approach to EVA, with the potential of reducing EVA crew overhead and consumable 
usage by two orders of magnitude (Abercromby et al. 2013). However, the role and impact of 
these variables on the overall probability of DCS is theoretical, with no empirical data available 
to support the theory. In addition, the acceptable level of DCS risk is dependent on treatment 
capability. 
 
A. PB Protocols Meet Acceptable DCS Risk Level, but with Poor WEI and High 
Consumable Use 
WEI is defined as EVA time divided by the amount of time spent preparing for the EVA, 
regardless of whether it is spent in a PB protocol or on tasks related to an EVA suit preparation. 
NASA’s historical µG EVA experience leads to an expectation of the threat of serious DCS 
being extremely small, primarily due to rigorous adherence to validated PB protocols.  Outside 
of the shuttle staged protocol, a unifying principle of all of these PB protocols is that there is a 
significant use of crewmember time and consumables before they exit the airlock. Current ISS 
WEI is less than 0.4.  This WEI accounts for PB, suit donning/doffing, and processing of the 
EVA suit and associated tools.  While this is tolerable for ISS EVAs, primarily due to their low 
frequency and the pre-existing EVA timelines, it will not be acceptable for future manned 
exploration missions, which will rely on a robust, efficient EVA program that assumes high-
frequency flexible exploration objectives of the destination target(s). Architectural assumptions 
for future surface exploration missions include up to multiple EVAs per person per day, which is 
unachievable given current spacecraft atmospheres and PB protocols. 
B. Exploration Missions Need to Define WEI and EVA Goals  
There are several potential DRM destinations that lie ahead in NASA’s manned exploration 
pathway.  Each DRM has its own unique combination of DCS risk factors, and the manner in 
which NASA plans to address those problems must be considered in advance of final design 
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plans for manned mission elements.  Prescribing an expected WEI target for any given DRM 
would drive overall design and engineering toward the most efficient use of crewmember time.  
 
An efficient exploration program needs an efficient EVA component. Infrequent, highly specific 
EVAs, such as those performed for ISS assembly, were effectively managed using existing PB 
protocols. Exploration missions will not have these same highly specified EVA timelines, but 
they will rely on more real-time science objectives and prioritization to determine EVA needs. 
While there are different ways to manage exploration EVA, the most flexible approach is to 
determine a minimal denitrogenation strategy that allows for on-demand EVA capabilities. This 
will most likely be met with some type of staged denitrogenation protocol.  Currently, a long PB 
time is needed before EVA from the ISS.  The denitrogenation may be effective in reducing the 
P(DCS), but even effective existing PB protocols are associated with a high incidence of VGE.  
Significant VGE insult of the lungs at 4.3 psia increases the probability of transporting VGE 
through the pulmonary vasculature or through a PFO (Foster et al. 2003, Moon 2000, Pilmanis et 
al. 1996).   
 
A future habitat atmosphere should have a low pN2 to shorten or eliminate the PB time.  One 
practical approach to reducing the pN2 is to increase the pO2 while also reducing the ambient 
pressure (Allen et al. 1969, Cooke & Robertson 1974, Horrigan & Waligora 1980).  A balance is 
achieved between the increased risk of fire at high O2 concentration and the decreased risk of 
DCS as pN2 is reduced in the habitat.  The concentration of O2 and, therefore, the risk of fire for 
a given ambient pressure can be reduced further if PIO2 is less than 150 mmHg, but not so low as 
to cause significant hypoxia (Conkin & Wessel 2008).  Not considered here are many other 
factors involved in living in a low-pressure habitat with an exotic breathing mixture, including a 
significant increase in electrical power for ventilation fans, increased insensible water loss 
(dehydration), valid issues about food preparation and steam sterilization (Brown et al. 1991, 
Campbell 2006), problems with voice communication (Roth 1967), and reduced response time in 
the event of a cabin atmosphere leak. 
   
C. Mitigating DCS through an Exploration Atmosphere may Introduce New Concerns  
The Engineering Directorate, Space and Life Sciences Directorate, Extravehicular Activity 
Office, and Astronaut Office all approved the proposed Exploration Atmosphere (8.0 psia / 32% 
O2), which was a result of the 2006 Exploration Atmospheres Working Group (EAWG).  This 
sought-after compromise provided a balance between mild hypoxia (PIO2 = 117 mmHg), 
flammability concerns in the pressurized living space, and the availability of quick, low-
overhead EVA capability with the trade of very little DCS risk (Campbell, 2006). In 2012, the 
results of the EAWG were re-evaluated by the Exploration Atmosphere Action Team. The 
Human Health and Performance subteam had the specific focus of evaluating the hypoxic 
symptoms potentially associated with the 8/32 atmosphere. This effort resulted in a 
recommendation to raise the pressure to 8.2 psia and O2% to 34%, resulting in a PIO2 = 128 
mmHg and no net change to the pN2 (Norcross et al. 2013). When coupling the 8.2/34 
Exploration Atmosphere with a variable-pressure EVA suit and a highly efficient suit 
donning/doffing technology such as the Multi Mission Space Exploration Vehicle (MMSEV) 
suitports, crew time and consumable use is efficiently maximized (Abercromby et al. 2013).  
However, there are undesired outcomes as well.  In order to meet the demands of decreased 
pressure and acceptable flammability risk, crewmembers will live in mild hypoxia).  This may 
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result in unrealized (or perhaps poorly understood) health consequences, or crewmembers may 
acclimate quickly with no hypoxic symptoms. Astronauts experienced a very similar hypoxic 
stress during the shuttle staged protocol at 10.2 psia / 26.5% O2 environment (PIO2 = 127 
mmHg). This level of hypoxia was not originally considered severe enough to warrant any 
specific research efforts.  However, data mining efforts through the Lifetime Surveillance of 
Astronaut Health (LSAH) and Life Science Data Archive (LSDA) repositories are currently 
underway to determine any evidence of hypoxia-related symptom occurrence during these 
flights.   
D. No Exploration Atmosphere Means Longer Denitrogenation Protocols 
Current and future spacesuit functionality requires decompression prior to EVA. Without the use 
of a staged denitrogentation protocol, such as proposed with the 8.2/34 Exploration Atmosphere, 
or a zero-PB EVA suit operating at higher pressures, denitrogenation protocols will remain 
lengthy. Much research could be performed to reduce the length of existing ISS PB protocols. 
Understanding how a break in PB affects P(DCS) would be a critical step. Additionally, 
understanding the differences in VGE, N2 washout, and micronuclei generation in the space 
flight environment would be of great benefit. In the end, an operational mitigation strategy that 
relies on long O2 PB as the primary strategy will result in longer more complicated EVA 
preparation timelines and higher consumable use and will reduce the flexibility and capabilities 
of exploration EVA.  
An example of the consumables savings available through use of the 8.2/34 Exploration 
Atmosphere is the reduction in the suit purge time by 6 min per EVA, achieving 80% O2 in the 
spacesuit rather than 95%. This modestly increases the P(DCS) risk, but the calculated savings of 
0.48 lb of gas and 6 minutes per person per EVA corresponds to more than 31 hours of crew time 
and 1800 lb of gas and tankage under the Constellation lunar architecture (Abercromby et al. 
2013). 
Of the available strategies to significantly reduce denitrogenation time while maintaining 
acceptable DCS risk, the Exploration Atmosphere strategy is more promising than either a high-
pressure EVA suit or an enhanced version of current ISS PB protocols.  
E. DCS Treatment is Undefined 
NASA operates under the maxim that prevention of DCS is better than treatment of DCS.  
Nowhere is that statement truer than when astronauts are far beyond low-Earth orbit, and 
effectively outside the reach of real-time medical guidance.   NASA should make every attempt 
to first use engineering controls and then operational procedures to mitigate DCS to acceptable 
risk levels and then properly prepare to treat a symptomatic crewmember. There may be no  
hypberbaric chamber capability available during future exploration missions, but if properly 
designed, a variable-pressure suit port-compatible EVA suit could provide almost instantaneous 
repressurization to the intermediate habitat pressure (likely 8.2 psia) and, if detached from the 
suit port and brought inside the cabin, could provide at least an additional 8.2 psia above the 
ambient cabin pressure. This simple application of Boyle’s Law goes a considerable distance in 
resolving most Type-I DCS pain (see Section 5 DCS Treatment Experience). 
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VII. Gaps    
We have described much of the evidence related to spaceflight DCS, and there still remain gaps 
in knowledge. The gaps are described in the following sub-sections and form the focus of the 
future NASA DCS research efforts. 
A. DCS1 – We have not defined the acceptable DCS risk with respect to the work 
efficiency index (WEI) for exploration scenarios 
Acceptable DCS risk for ISS assembly was defined as part of the PB reduction program. By 
validating operational PB protocols against this acceptable risk level, NASA has successfully 
prevented both serious Type II DCS and Type I pain-only DCS. This acceptable risk level is 
currently under review by the NASA Headquarters Chief Health and Medical Office to be 
included as a new human spaceflight standard in the EVA section of NASA-STD-3001 Volume 
1. This standard will dictate the minimum standard for which all future PB protocols will need to 
be tested against. The focus of this standard was to protect against long- and short-term human 
health consequences, but it does not define any guidelines for WEI, crew time, or consumables.  
The target for gap closure is the complete approval of the NASA-STD-3001 Volume 1 update 
for EVA purposes and then a later update to NASA-STD-3001 for a DCS risk standard related to 
vehicle decompressions to the Exploration Atmosphere, which exposes the entire crew to a DCS 
risk. 
B. DCS2 – We do not know the contribution of specific DCS risk factors to the 
development of DCS in the Space Flight Exploration Environment 
As previously discussed, it is well accepted that gas bubbles through some mechanism are the 
initial cause of the symptoms of DCS.  This gas bubble formation and growth can potentially 
occur during decompressions from higher to lower ambient pressure, but the mechanisms that 
cause bubble formation, growth, and elimination are not well understood. It is known that 
physiological and environmental factors contribute to DCS, but there is a lack of information on 
their importance or interrelationships in the space flight environment.  
The target for gap closure is to obtain an effect size as a function of individual variance for each 
risk factor of interest. Depending on the statistical significance of a given risk factor, it may then 
be included in a comprehensive DCS prediction model. 
C. DCS3 – We do not know the mission related factors that contribute to DCS risk 
The characteristics of the ISS EVA environment are well understood, but this is not the case with 
new DRMs. For instance, it is known that activity level during depressurization has a significant 
effect on the development of DCS. At any given depressurization, an increase in activity level 
increases the DCS risk. In addition, certain movements tend to be more provocative than others, 
possibly due to the forces generated by movement in different joints. NASA is going to locations 
where there is either no or little human EVA experience. Many factors contribute to DCS risk, 
and all of these factors need to be understood in order to provide updates to models and/or to the 
development of EVA simulators for PB validation trials. 
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The target for gap closure is to develop an EVA simulator for use in PB validation trials; to 
provide inputs related to WEI, EVA overhead, crew time, and consumable usage in relation to 
achieving acceptable DCS risk (Gap 1); and to obtain an effect size as a function of individual 
variance for each risk factor of interest in order to consider it for inclusion in a comprehensive 
DCS prediction model. 
D. DCS4 – We do not know to what extent physiological and environmental factors can 
be incorporated and validated in a model of DCS for micro and reduced gravity 
Existing DCS prediction models have differing levels of credibility for µG EVA from an Earth-
normal atmosphere habitat, but none of these models are validated for the Exploration 
environments, including planetary gravity, the 8.2/34 Exploration Atmosphere, and high-
frequency EVA. Research efforts are underway to define a DCS treatment model. There is also a 
need for a comprehensive DCS prediction model that is both user-friendly and applicable across 
all DRMs. Finally, a tissue saturation model is proposed to understand tissue saturation rates 
with- and without exercise conditions. 
The targets for gap closure are validated DCS risk and DCS treatment models for the expected 
exploration environments that meet NASA-STD-7009 requirements. 
E. DCS5 – We do not know what validated procedures will adequately prevent DCS 
Validated procedures to prevent DCS exist for the ISS but not for Exploration Mission DRMs. 
Current DCS prediction models do not extrapolate to the expected Exploration environment and 
can only be used to develop initial estimates for Exploration protocols, which must be validated 
through ground testing prior to operational implementation. 
The targets for gap closure are PB protocols that meet the DCS1 acceptable risk standard for 
future exploration missions. 
F. DCS6 – We do not know what new developments related to DCS will come from other 
investigators 
Through active involvement in DCS research for the past 30 years, the current status of DCS risk 
factors, treatment modalities, detection methods, and prediction models is well known to NASA, 
but NASA is not the only institution performing DCS research. There remains a solid academic, 
military, and aerospace presence interested in DCS, and their developments need to be closely 
monitored. 
The target for this gap closure is automatically met assuming the HRP EVA Discipline team 
regularly reviews the scientific literature and attends relevant scientific meetings. Closure is also 
met through regular research plan reviews by external experts as per HRP policy. 
G. DCS7 – We have not validated procedures to adequately treat DCS in the spaceflight 
environment should it occur 
DCS treatment protocols for altitude DCS often involve hyperbaric oxygen treatment. These 
treatment protocols are based on aviation scenarios and assume a crewmember’s return to 
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ground. In space, this may not be possible, and we need to understand the potential for treating 
DCS with the use of expected in-situ resources. 
 
Additionally, we need to consider whether there are any long-term outcomes of spaceflight DCS 
that need to be followed over the course of a crewmember’s life. 
 
The target for gap closure is inputs to DCS treatment procedures for each DRM and 
recommendations to the LSAH project for medical tests needed to evaluate long-term health 
consequences of spaceflight DCS. 
VIII. Conclusion 
 
DCS is an occupational health and mission hazard that requires mitigation as an astronaut moves 
from a higher pressure habitat into the lower pressure EVA suit. To date, DCS has been 
effectively mitigated through rigorous adherence to PB protocols validated specifically for the 
µG EVA environment. While effective, these protocols are complex and require significant pre-
flight training, inflight crew time, and consumable usage. Furthermore, utilization of the 
Exploration Atmosphere (8.2 psi/34% O2), suit ports, and variable-pressure suits, as well as the 
inability to rapidly deorbit to receive medical treatment, means that existing DCS risk mitigation 
protocols and data sets are not applicable to future exploration missions.   
 
The acceptable risk for DCS has been defined in the NASA Human Spaceflight Standards; 
therefore, the next step will be to develop and validate procedures, protocols, and 
countermeasures to meet this standard effectively and efficiently for the range of nominal and 
off-nominal atmospheres and decompression profiles that crewmembers may experience during 
future exploration missions.  
 
To improve efficiency for a sea-level atmosphere, data are needed on the potential differences in 
bubble formation and N2 elimination while in µG. To improve safety and efficiency for any 
atmosphere, data are needed to describe the consequences of a break in PB. Finally, the 
opportunity exists to mitigate DCS primarily through engineering controls by the use of the 8.2 
psia/34% O2 Exploration Atmosphere, suit ports, and variable-pressure EVA suits. While 
promising, these technologies are poorly understood from a physiological perspective and will 
demand rigorous development and testing of DCS mitigation strategies and procedures prior to 
operational implementation.  
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XI. List of Acronyms 
 
1-G   Earth-normal gravity 
AFB   Air Force Base 
AGE   arterial gas emboli 
Ar   argon 
ATA   absolute atmospheric pressure 
ATM   atmospheric pressure 
BGI   bubble growth index 
BMI   body mass index 
BTA   bends treatment adapter 
CEVIS   cycle ergometer with vibration isolation and stabilization 
CM   cutis marmorata 
CNS   central nervous system 
CO2   carbon dioxide 
DCS   decompression sickness 
DCIEM  Defense and Civil Institute of Environmental Medicine 
ΔP   pressure difference 
DT   Doppler technician 
EMU   Extravehicular Mobility Unit 
ETA   environmental test article 
EVA   extravehicular activity 
FFW   feet of fresh water 
FN2   fraction of nitrogen in a bubble 
FSW   feet of sea water 
ft   foot 
GLO ground-level oxygen 
HBO   hyperbaric oxygen 
hr   hour 
ID identification 
ISLE   in-suit light exercise 
ISS   International Space Station 
JSC   Johnson Space Center 
kg   kilogram 
k number of gas species in tissue 
kPa   kilopascal 
lbf pound force 
µG   microgravity 
m   meter 
min   minute 
ml   milliliter 
mmHg   millimeters of mercury (pressure) 
MO Medical Officer 
n sample size 
N Newtons of force 
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NASA   National Aeronautics and Space Administration 
NBL   Neutral Buoyancy Laboratory 
NEEMO  NASA Extreme Environment Mission Operations 
N2   nitrogen 
O2   oxygen 
P1   initial pressure 
P1N2   computed tissue N2 partial pressure 
P2   final pressure 
PB   prebreathe 
P(DCS)  probability of decompression sickness 
P(Grade IV VGE) probability of Grade IV VGE 
PI Principal Investigator 
P(Serious DCS) probability of serious decompression sickness 
PFO   patent foramen ovale 
PIN2   inspired (wet) partial pressure of nitrogen 
PIO2   inspired (wet) partial pressure of oxygen 
pN2   partial pressure of nitrogen 
pO2    partial pressure of oxygen 
PRP Prebreathe Reduction Protocol 
psia   pounds per square inch absolute 
PTC Physiological Training Chamber 
rc   critical radius 
R-value  ratio-value used by NASA, equivalent to P1N2 / P2 
SCUBA  self-contained underwater breathing apparatus 
SD   standard deviation 
STPD   standard temperature (0 Celsius), pressure (1 ATM), dry gas  
STS   Space Transportation System 
TR   tissue ratio 
TT V Treatment Table V 
TT VI Treatment Table VI 
U.S.   United States 
USAF   United States Air Force 
USN TT V  United States Navy Treatment Table V 
VGE   venous gas emboli 
VO2 peak  measured peak oxygen consumption as ml*kg
-1
*min
-1  
WW II   World War II 
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Appendix A: Computer-based DCS Modeling: Description of Models 
 
Data collected from 1982 to the present are archived in the JSC Hypobaric Decompression 
Sickness Database.  Results from specific PB protocols were used to accept or reject the protocol 
for specific applications.  Because each protocol is unique, it is also possible to statistically 
describe large subsets of data to create predictive equations (models), which we call Probabilistic 
Modeling.  We have created two classes of predictive models: statistical and biophysical.  The 
statistical models compute the probability of DCS based on information from our best research 
data or best published data in cases where our research data are insufficient to address an issue.  
We have also extended the methodology to create a probability model for acute mountain 
sickness, a transient possibility on future exploration missions.  The biophysical (bubble) models 
provide information about bubble growth in tissue, which is then linked to the probability of 
DCS through logistic regression, or even through a statistical survival model. 
 
Variables that describe a test are combined to create a decompression dose.  For each dose, there 
is a DCS and VGE response, or outcome.  The statistical process optimizes the expression for 
dose to compute the best probability for the response.  The dose includes information about the 
PB procedure (exercise and rest intervals), the suit pressure, the time spent at altitude, 
information on whether exercise is performed at altitude, information about the person in the test 
(VO2 peak, gender, age) (in some cases), and information on whether the test was performed 
under a microgravity simulation (adynamia). 
  
There are multiple probability models available that describe the risk of DCS, forced descent 
DCS, serious DCS, VGE, and Grade IV VGE.  Most, but not all, of these models are 
documented as contractor reports or science journal publications, and most are contained in the 
ATOM program; however, additional BASIC programs have been written to compute 95% 
confidence intervals for the best estimate of risk that are not part of the ATOM program.  As new 
data become available, statistical and biophysical predictive models are updated.  The following 
is a summary list of statistical probability models available to evaluate new potential PB 
protocols before a new protocol is proposed for testing. 
 
Hill Equation Model for total DCS and VGE, n = 927 
 
Hill Equation Model for symptoms that would stop an EVA, n = 698 
 
Reference:  Conkin J, BF Edwards, JM Waligora, J Stanford, Jr., JH Gilbert, III, DJ Horrigan, Jr.  
Updating empirical models that predict the incidence of aviator decompression sickness and 
venous gas emboli for shuttle and space station extravehicular operations. NASA Technical 
Memorandum 100456 Update, Johnson Space Center, Houston, TX. October 1990.    
Regression contained in the ATOM program. 
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Survival DCS Model, n = 1075 
Reference:  Conkin J, KV Kumar, MR Powell, PP Foster, JM Waligora.  A probability model of 
hypobaric decompression sickness based on 66 chamber tests. Aviat. Space Environ. Med. 1996; 
67:176-83. 
Regression contained in the ATOM program. 
 
Reference:  Thompson LA, Chhikara RS, Conkin J.  Cox proportional hazards models for 
modeling the time to onset of decompression sickness in hypobaric environments.  NASA 
Technical Publication 2003-210791, Houston: Johnson Space Center, March 2003. 
 
Reference:  Thompson LA, Chhikara RS, Conkin J.  Evaluation of Cox proportional hazards 
models for time to onset of decompression sickness in hypobaric environments.  ISSO Y2002 
Annual Report, Houston: University of Houston and University of Houston at Clear Lake, p. 13-
20, Spring 2003. 
 
Forced Descent DCS Model, n = 4766 
Reference:  Van Liew HD, Burkard ME, Conkin J. Testing of hypotheses about altitude 
decompression sickness by statistical analyses. Undersea Hyperbaric Med. 1996; 23:225-33. 
Regression contained in the ATOM program. 
 
Adynamia DCS and VGE Models, n = 1401 
Reference:  Conkin J, Powell MR.  Lower body adynamia as a factor to reduce the risk of 
hypobaric decompression sickness.  Aviat. Space Environ. Med. 2001; 72:202-14. 
Regression contained in the ATOM program. 
 
Serious DCS Model, n = 79,366 
Reference:  Conkin J.  Evidence-based approach to the analysis of serious decompression 
sickness with application to EVA astronauts.  NASA Technical Publication 2001-210196, 
Houston: Johnson Space Center, January 2001. 
Regression contained in the ATOM program. 
 
Reference:  Thompson LA, Chhikara RS, Conkin J, Powell MR.  Determination of risk of 
serious decompression sickness amoung astronauts involved in space extravehicular activity.  
ISSO Y2001 Annual Report, Houston: University of Houston and University of Houston at Clear 
Lake, p. 82-84, Spring 2002. 
 
Reference:  Conkin J, Klein JS, Acock KE.  Description of 103 cases of hypobaric 
decompression sickness from NASA-sponsored research (1982 to 1999).  NASA Technical 
Publication 2003-212052 Houston: Johnson Space Center, July, 2003. 
 
Grade IV VGE Model, n = 549 (NASA-only data) 
Reference:  Conkin J.  unpublished regression given the age, tissue ratio, duration of the 
exposure, and if the subject was adynamic or not during the exposure.   
Regression contained in the ATOM program. 
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79 
 
Reference:  Thompson LA, Conkin J, Chhikara RS, Powell MR.  Modeling Grade IV venous gas 
emboli using a limited failure population model with random effects.  NASA Technical 
Publication 2002-210781, Houston: Johnson Space Center, June 2002. 
 
Reference:  Conkin J, Powell MR, Gernhardt ML.  Age affects severity of venous gas emboli on 
decompression from 14.7 to 4.3 psia.  Aviat. Space Environ. Med. 2003;74:1142-1150.   
Note: the model does not include an expression for tissue ratio, so any comparison of observed 
Grade IV to these estimates must be from tests “like” the tests used in this model (i.e., resting 
and exercise prebreathes > 180 min). 
 
Reference:  Thompson LA, Chhikara RS, Conkin J, Powell MR.  A limited failure population 
model for onset of Grade IV venous gas emboli.  ISSO Y2001 Annual Report, Houston: 
University of Houston and University of Houston at Clear Lake, p. 22-29, Spring 2002. 
 
Cuff 1, 2, 4 (NASA), 4(literature) DCS Models, n=194, 914, 914, 6859 
Reference:  Conkin J.  unpublished regressions based only on the tissue ratio.   
Regression contained in the ATOM program. 
 
Exercise Adynamia DCS Models (NASA, n = 154) and (Research, n = 222) from PRP Data 
Reference:  Conkin J, Gernhardt ML, Powell MR, Pollock N  A probability model of 
decompression sickness at 4.3 psia after exercise prebreathe.  NASA Technical Publication 
NASA/TP-2004-213158 Houston:  Johnson Space Center, December 2004. 
 
Exercise Adynamia DCS Models (NASA, n = 204) from PRP Data (at conclusion of V-5 
test) 
Reference:  Conkin J.  unpublished regressions based only on the exercise tissue ratio.   
 
USAF Altitude Decompression Sickness Risk Assessment Computer (ADRAC) 
Note: The computer program runs on a PC but has limited application to the NASA EVA 
program.  
Reference:  Pilmanis AA, Petropoulos LJ, Kannan N, Webb JT.  Decompression sickness risk 
model: development and validation by 150 prospective hypobaric exposures.  Aviat Space 
Environ Med 2004; 75:749-59. 
 
Bubble Growth Index Model - biophysical bubble model optimized to predict hypobaric 
DCS 
Note 1:  model is currently optimized for a subset of NASA DCS data, with plans to include 
relevant USAF data from the Air Force Research Laboratory Altitude Decompression Sickness 
Research Database archived at Wright-Patterson AFB.  The model has the provision to account 
for exercise during prebreathe, but not a micronuclei size distribution.  
 
Reference: Gernhardt ML.  Development and evaluation of a decompression stress index based 
on tissue bubble dynamics. [Dissertation].  Philadelphia, PA: University of Pennsylvania, 1991. 
Risk of Decompression Sickness (DCS) 
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Note 2: Dr. Srini Srinivasan made significant advances in the biophysical description of bubble 
growth in tissue but has since retired and did not leave any useful computer code or predictive 
equation based on optimization of his bubble model to empirical data.  For completeness, two of 
his published works are documented: 
 
Reference: Srinivasan RS, Gerth WA, Powell MR.  Mathematical model of diffusion-limited 
evolution of multiple gas bubbles in tissue.  Ann Biomed Eng 2003; 31:471-81. 
Reference:  Srinivasan RS, Gerth WA, Powell MR.  A mathematical model of diffusion-limited 
gas bubble dynamics in unstirred tissue with finite volume.  Ann Biomed Eng 2002; 30:232-46.  
 
Probability Model to Predict Acute Mountain Sickness 
Note:  Living at a high altitude with an enriched O2 atmosphere can still result in mild hypoxia if 
an increase in the flammability of future spacecraft atmospheres is avoided.  It is unclear what 
the true hypoxic dose is under these NASA-unique conditions.  A non-validated statistical 
regression model based on limited data is available to assess the probability of acute mountain 
sickness. 
 
Reference: Conkin J, Wessel JH III.  Critique of the equivalent air altitude model.  Aviat Space 
Environ Med 2008; 79:975-82. 
 
Reference: Conkin J, Wessel JH III.  A model to predict acute mountain sickness in future 
spacecraft.  NASA Technical Publication NASA/TP-2009-214791, Houston: Johnson Space 
Center, July 2009. 
 
Unit Pulmonary Toxicity Dose (UPTD) Model 
Note: The use of 100% O2 in aerospace applications causes concerns about O2 toxicity.  A 
mathematical expression of UPTD is available to us to address concerns about limits to 
hyperbaric O2 exposure.  
Reference:  Lambertsen CJ, Clark JM, Gelfand R, Hopkins E.  Improved pulmonary O2 toxic 
dose/effect prediction.  Annual Meeting of the Undersea and Hyperbaric Medical Society, 
abstract #33, p. 19, June 26-29, 1999. 
 
Regression contained in the ATOM program. 
